<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="hyperchol" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">hyperchol</book-part-id>
      <title-group>
        <title>Familial Hypercholesterolemia</title>
        <alt-title alt-title-type="alt-title">Synonyms: Hypercholesterolemia, Autosomal Dominant; Hyperlipoproteinemia Type IIA; Familial Hypercholesterol&#x000e6;mia</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Youngblom</surname>
            <given-names>Emily</given-names>
          </name>
          <degrees>PhD, MPH</degrees>
          <aff>Stanford Center for Inherited Cardiovascular Disease<break/>Stanford, California<break/>University of Washington School of Public Health<break/>Seattle, Washington</aff>
          <email>eyoungb@uw.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pariani</surname>
            <given-names>Mitchel</given-names>
          </name>
          <degrees>MS, LCGC</degrees>
          <aff>Stanford Center for Inherited Cardiovascular Disease<break/>Stanford, California</aff>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Knowles</surname>
            <given-names>Joshua W</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <aff>Stanford Center for Inherited Cardiovascular Disease<break/>Stanford, California</aff>
          <email>knowlej@stanford.edu</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>2</day>
          <month>1</month>
          <year>2014</year>
        </date>
        <date date-type="updated">
          <day>8</day>
          <month>12</month>
          <year>2016</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="fhm" document-type="chapter">Familial Hemiplegic Migraine</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="hi" document-type="chapter">Familial Hyperinsulinism</related-object>
      <abstract id="hyperchol.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Familial hypercholesterolemia (FH) is characterized by severely elevated LDL cholesterol (LDL-C) levels that lead to atherosclerotic plaque deposition in the coronary arteries and proximal aorta at an early age, leading to an increased risk for cardiovascular disease. Xanthomas (patches of yellowish cholesterol buildup) may worsen with age as a result of extremely high cholesterol levels. Xanthomas can occur around the eyelids and within the tendons of the elbows, hands, knees, and feet. In FH, the more common cardiovascular disease is coronary artery disease (CAD), which may manifest as angina and myocardial infarction; stroke occurs more rarely. Untreated men are at a 50% risk for a fatal or non-fatal coronary event by age 50 years; untreated women are at a 30% risk by age 60 years.</p>
          <p>An estimated 70%-95% of FH results from a heterozygous pathogenic variant in one of three genes (<italic toggle="yes">APOB, LDLR, PCSK9</italic>). FH is the most common inherited cardiovascular disease, with a prevalence of 1:200-250. FH likely accounts for 2%-3% of myocardial infarctions in individuals younger than age 60 years.</p>
          <p>In contrast, homozygous FH (HoFH) results from biallelic (homozygous or compound heterozygous) pathogenic variants in one of these known genes (<italic toggle="yes">APOB</italic>, <italic toggle="yes">LDLR</italic>, <italic toggle="yes">PCSK9</italic>). Most individuals with HoFH experience severe CAD by their mid-20s and the rate of either death or coronary bypass surgery by the teenage years is high. Severe aortic stenosis is also common.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>Several formal diagnostic criteria exist for FH. The diagnostic criteria most widely used in Western countries include: extreme hypercholesterolemia (untreated adults with LDL-C&#x0003e;190 mg/dL or total cholesterol levels &#x0003e;310 mg/dL; untreated children/adolescents with LDL-C levels &#x0003e;160 mg/dL or total cholesterol levels &#x0003e;230 mg/dL); history of premature CAD or other CVD; xanthomas; corneal arcus; and a family history of features suggestive of FH. The diagnosis of FH can also be established by identification of a heterozygous pathogenic variant in one of the three genes (<italic toggle="yes">APOB</italic>, <italic toggle="yes">LDLR</italic>, and <italic toggle="yes">PCSK9</italic>) known to be associated with FH.</p>
          <p>The diagnosis of HoFH can be established in a proband by identification of biallelic pathogenic variants in one of the three genes (<italic toggle="yes">APOB</italic>, <italic toggle="yes">LDLR</italic>, and <italic toggle="yes">PCSK9</italic>) known to be associated with FH.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations</italic>: Adults with FH: reduce CAD risk factors including cessation of smoking, regular physical activity, healthy diet and weight control; treatment of hypertension; low-dose aspirin in high-risk individuals; pharmacotherapy (statins with additional medications as needed) to reduce lipid levels; referral to a lipid specialist if necessary to reduce LDL-C levels. Children with FH: referral to a lipid specialist; diet and lifestyle modifications; statins can be used in children starting around age eight years. Children and adults with HoFH: referral to a lipid specialist or specialized center for management of multiple drug therapy; LDL apheresis is often required; liver transplantation in rare circumstances.</p>
          <p><italic toggle="yes">Prevention of primary manifestations:</italic> Statin-based therapy with addition of other medications as needed, in combination with a heart-healthy diet (including reduced intake of saturated fat and increased intake of soluble fiber to 10-20 g/day); increased physical activity; not smoking.</p>
          <p><italic toggle="yes">Surveillance:</italic> Children with an established diagnosis of FH or risk factors for FH (e.g., elevated serum cholesterol, a family history of FH, a family history of premature CAD or other CVD) should have lipid levels checked before age ten years. All individuals with FH should have lipid levels monitored as recommended. Individuals with HoFH should be monitored with various imaging modalities (including echocardiograms, CT angiograms and cardiac catheterization) as recommended.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Smoking, high intake of saturated and trans unsaturated fat, excessive intake of cholesterol, sedentary lifestyle, obesity, hypertension, and diabetes mellitus.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> Early diagnosis and treatment of first-degree and second-degree relatives at risk for FH can reduce morbidity and mortality. The genetic status of at-risk family members can be clarified by either: (1) molecular genetic testing if the pathogenic variant has been identified in an affected family member; or (2) measurement of LDL-C concentration.</p>
          <p><italic toggle="yes">Pregnancy management:</italic> Pregnant women should incorporate all the recommended lifestyle changes including low-saturated fat intake, no smoking, and high dietary soluble fiber. Statins are contraindicated in pregnancy due to concerns for teratogenicity and should be discontinued prior to conception. Bile acid binding resins (e.g., colesevelam) are generally considered safe (Class B for pregnancy), and LDL apheresis is also occasionally used if there is evidence of established CAD.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>Heterozygous familial hypercholesterolemia (FH) and homozygous familial hypercholesterolemia (HoFH) are inherited in an autosomal dominant manner.</p>
          <p>Almost all individuals diagnosed with FH have an affected parent; the proportion of FH caused by a <italic toggle="yes">de novo</italic> pathogenic variant is unknown but appears to be extremely low. Each child of an individual with FH has a 50% chance of inheriting the pathogenic variant.</p>
          <p>If both parents have FH, each child has a 50% chance of having FH, a 25% chance of having HoFH, and a 25% chance of not having FH.</p>
          <p>If the pathogenic variant has been identified in a family member with FH (or if both pathogenic variants have been identified in a family member with HoFH), prenatal testing for pregnancies at increased risk is possible.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="hyperchol.GeneReview_Scope">
        <title><italic toggle="yes">GeneReview</italic> Scope</title>
        <table-wrap id="hyperchol.Tc" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_hyperchol.Tc_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Familial Hypercholesterolemia: Included Phenotypes</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_hyperchol.Tc_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1">
                  <list list-type="bullet">
                    <list-item>
                      <p>Familial hypercholesterolemia (FH, also referred to as heterozygous FH or HeFH)</p>
                    </list-item>
                    <list-item>
                      <p>Homozygous hypercholesterolemia (HoFH)</p>
                    </list-item>
                  </list>
                </td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="hyperchol.Diagnosis">
        <title>Diagnosis</title>
        <p>In this <italic toggle="yes">GeneReview</italic>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Familial hypercholesterolemia (FH) refers to hypercholesterolemia resulting from a heterozygous pathogenic variant in one of several genes (<italic toggle="yes">APOB, LDLR,</italic> and <italic toggle="yes">PCSK9</italic>); it is also referred to as heterozygous FH (HeFH). FH is a relatively common disorder (prevalence 1:200-1:250).</p>
          </list-item>
          <list-item>
            <p>Homozygous FH (HoFH) refers to familial hypercholesterolemia resulting from biallelic (including true homozygous and compound heterozygous) pathogenic variants in one of these same genes (<italic toggle="yes">APOB, LDLR,</italic> and <italic toggle="yes">PCSK9</italic>). HoFH is much rarer than FH (prevalence 1:160,000 to 1:250,000 [<xref ref-type="bibr" rid="hyperchol.REF.nordestgaard.2013.3478">Nordestgaard et al 2013</xref>, <xref ref-type="bibr" rid="hyperchol.REF.cuchel.2014.2146">Cuchel et al 2014</xref>].</p>
          </list-item>
        </list>
        <sec id="hyperchol.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Familial hypercholesterolemia (FH) <bold>should be suspected</bold> in individuals with the following findings</p>
          <list list-type="bullet">
            <list-item>
              <p>Extreme hypercholesterolemia</p>
              <list list-type="bullet">
                <list-item>
                  <p>Adults (untreated):</p>
                  <list list-type="bullet">
                    <list-item>
                      <p>Low-density lipoprotein cholesterol (LDL-C) levels &#x0003e;190 mg/dL (&#x0003e;4.9 mmol/L)</p>
                    </list-item>
                    <list-item>
                      <p>Total cholesterol levels &#x0003e;310 mg/dL (&#x0003e;8 mmol/L)</p>
                    </list-item>
                  </list>
                </list-item>
                <list-item>
                  <p>Children/adolescents (untreated):</p>
                  <list list-type="bullet">
                    <list-item>
                      <p>LDL-C levels &#x0003e;130 mg/dL (&#x0003e;3.4 mmol/L)</p>
                    </list-item>
                    <list-item>
                      <p>Total cholesterol levels &#x0003e;230 mg/dL (&#x0003e;6 mmol/L)</p>
                    </list-item>
                  </list>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>History of premature coronary artery disease (CAD) or other cardiovascular disease (CVD) (e.g., angina pectoris, myocardial infarction, peripheral vascular disease)</p>
            </list-item>
            <list-item>
              <p>Physical examination findings (e.g., xanthomas, corneal arcus)</p>
            </list-item>
            <list-item>
              <p>Family history of premature CAD and/or CVD</p>
            </list-item>
          </list>
        </sec>
        <sec id="hyperchol.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>Currently three formal diagnostic criteria for FH are widely used in Western countries. (See <xref ref-type="bibr" rid="hyperchol.REF.haradashiba.2012.1043">Harada-Shiba et al [2012]</xref> for criteria used in non-Western countries.)</p>
          <list list-type="bullet">
            <list-item>
              <p>
                <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://nlaresourcecenter.lipidjournal.com/Content/PDFs/Tables/5.pdf">US MEDPED Program</ext-link>
              </p>
            </list-item>
            <list-item>
              <p>
                <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK53810/">UK Simon Broome Familial Hypercholesterol&#x000e6;mia Registry</ext-link>
              </p>
            </list-item>
            <list-item>
              <p>
                <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://nlaresourcecenter.lipidjournal.com/Content/PDFs/Tables/4.pdf">Dutch Lipid Clinic Network</ext-link>
              </p>
            </list-item>
          </list>
          <p>All three criteria rely on a combination of the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Extreme hypercholesterolemia</p>
            </list-item>
            <list-item>
              <p>History of premature CAD or other CVD</p>
            </list-item>
            <list-item>
              <p>Findings on physical examination</p>
            </list-item>
            <list-item>
              <p>Family history of premature CAD or other CVD</p>
            </list-item>
            <list-item>
              <p>Identification of a pathogenic variant in a gene known to be associated with FH (see <xref ref-type="table" rid="hyperchol.T.molecular_genetic_testing_us">Table 1</xref>)</p>
            </list-item>
          </list>
          <p>
            <bold>Extreme hypercholesterolemia</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Adults (untreated):</p>
              <list list-type="bullet">
                <list-item>
                  <p>LDL-C levels &#x0003e;190 mg/dL (&#x0003e;4.9 mmol/L)</p>
                </list-item>
                <list-item>
                  <p>Total cholesterol levels &#x0003e;310 mg/dL (&#x0003e;8 mmol/L)</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Children or adolescents (untreated):</p>
              <list list-type="bullet">
                <list-item>
                  <p>LDL-C levels &#x0003e;160 mg/dL (&#x0003e;4 mmol/L)</p>
                </list-item>
                <list-item>
                  <p>Total cholesterol levels &#x0003e;230 mg/dL (&#x0003e;6 mmol/L)</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p>Note: (1) A non-fasting lipid panel can be obtained first in the initial evaluation of children, and, if abnormal or borderline, a fasting LDL-C level should be obtained [<xref ref-type="bibr" rid="hyperchol.REF.martin.2013">Martin et al 2013</xref>]. Elevation of two consecutive LDL-C levels is often recommended to confirm the diagnosis. (2) Age-specific LDL-C or total cholesterol levels are more specific in determining the likelihood of FH; for instance, LDL-C or total cholesterol levels &#x0003e;95th percentile for age, gender, and country [<xref ref-type="bibr" rid="hyperchol.REF.starr.2008.791">Starr et al 2008</xref>, <xref ref-type="bibr" rid="hyperchol.REF.nordestgaard.2013.3478">Nordestgaard et al 2013</xref>]. (3) Computer (including mobile or smart phone-based) applications (see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.appdropp.com/ios/fh-diagnosis/543676258">FH Diagnosis</ext-link>) can assist with the determination of the likelihood of FH based on the formal diagnostic criteria.</p>
          <p>
            <bold>History of premature CAD or other CVD</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Angina pectoris</p>
            </list-item>
            <list-item>
              <p>Myocardial infarction</p>
            </list-item>
            <list-item>
              <p>Peripheral vascular diseases</p>
            </list-item>
          </list>
          <p>Note: Although stroke is possible, it is less common in FH than premature CAD [<xref ref-type="bibr" rid="hyperchol.REF.huxley.2003.22">Huxley et al 2003</xref>].</p>
          <p>
            <bold>Physical examination findings</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Xanthomas (patches of yellowish cholesterol buildup). Common locations include around the eyelids, tendons of the elbows, hands, knees, and feet, particularly the Achilles tendon. Interdigital xanthomas occur in individuals with homozygous FH.</p>
            </list-item>
            <list-item>
              <p>Corneal arcus (white, gray, or blue opaque ring in the corneal margin). Because this becomes increasingly common in the general population with age, it is only diagnostic in younger individuals, particularly before age 45 years.</p>
            </list-item>
          </list>
          <p>Note: As statin treatment has become more common, it is possible that individuals have fewer visible signs of FH, complicating the application of the diagnostic criteria.</p>
          <p>
            <bold>Family history of any of the following</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Familial hypercholesterolemia</p>
            </list-item>
            <list-item>
              <p>High levels of LDL-C</p>
            </list-item>
            <list-item>
              <p>Early-onset (i.e., age &#x0003c;50 years) CAD (especially myocardial infarction)</p>
            </list-item>
            <list-item>
              <p>Xanthomas</p>
            </list-item>
          </list>
          <p><bold>Identification of a pathogenic variant in a gene known to be associated with FH</bold> (see <xref ref-type="table" rid="hyperchol.T.molecular_genetic_testing_us">Table 1</xref>) is the gold standard for diagnosis accepted in many countries [<xref ref-type="bibr" rid="hyperchol.REF.nordestgaard.2013.3478">Nordestgaard et al 2013</xref>].</p>
          <list list-type="bullet">
            <list-item>
              <p>The likelihood of identifying a pathogenic variant by molecular testing increases with higher LDL-C levels.</p>
            </list-item>
            <list-item>
              <p>In the United States, genetic testing is recommended when other laboratory tests have not definitively established the diagnosis of FH.</p>
            </list-item>
          </list>
          <p>Molecular genetic testing approaches can include <bold>serial single-gene testing</bold> and use of a <bold>multi-gene panel</bold>.</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Serial single-gene testing</bold> can be considered. Sequence analysis of <italic toggle="yes">LDLR</italic> is performed first followed by <italic toggle="yes">LDLR</italic> deletion/duplication analysis if no pathogenic variant is found. Sequence analysis of <italic toggle="yes">APOB</italic> and <italic toggle="yes">PCSK9</italic> can be performed next if no pathogenic variant is found.</p>
            </list-item>
            <list-item>
              <p><bold>A multi-gene panel</bold> that includes <italic toggle="yes">APOB</italic>, <italic toggle="yes">LDLR</italic>, <italic toggle="yes">PCSK9</italic> and other genes of interest (see <xref ref-type="sec" rid="hyperchol.Differential_Diagnosis">Differential Diagnosis</xref>) may also be considered. Note: (1) The genes included and the sensitivity of multi-gene panels vary by laboratory and over time. (2) Some multi-gene panels may include genes not associated with FH; thus, clinicians need to determine which multi-gene panel provides the best opportunity to identify the genetic cause of a condition at the most reasonable cost while limiting secondary findings. (3) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing based tests.</p>
            </list-item>
          </list>
          <table-wrap id="hyperchol.T.molecular_genetic_testing_us" orientation="portrait" position="anchor">
            <label>Table 1. </label>
            <caption>
              <p>Molecular Genetic Testing Used in Familial Hypercholesterolemia (FH)</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_2" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_2">Proportion of FH Attributed to Pathogenic Variants in This Gene&#x000a0;<sup>2</sup></th>
                  <th id="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_3" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Proportion of Pathogenic Variants&#x000a0;<sup>3</sup> Detectable by This Method</th>
                </tr>
                <tr>
                  <th headers="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_3" id="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">Sequence analysis&#x000a0;<sup>4</sup></th>
                  <th headers="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_3" id="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>5</sup></th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">APOB</italic>
                  </td>
                  <td headers="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1%-5%</td>
                  <td headers="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_3 hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;99%</td>
                  <td headers="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_3 hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">1 individual&#x000a0;<sup>6</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">LDLR</italic>
                  </td>
                  <td headers="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">60%-80%</td>
                  <td headers="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_3 hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;90%&#x000a0;<sup>7</sup></td>
                  <td headers="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_3 hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">~2.5%-10%&#x000a0;<sup>8</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">PCSK9</italic>
                  </td>
                  <td headers="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">0%-3%</td>
                  <td headers="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_3 hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">~100%</td>
                  <td headers="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_3 hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">None reported&#x000a0;<sup>9</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Unknown&#x000a0;<sup>10,&#x000a0;11</sup></td>
                  <td headers="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">20%-40%</td>
                  <td headers="hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_1_3 hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_2_1 hd_h_hyperchol.T.molecular_genetic_testing_us_1_1_2_2" valign="middle" colspan="2" align="left" rowspan="1">NA</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="hyperchol.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="hyperchol" object-id="hyperchol.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="hyperchol.TF.1.2">
                <label>2. </label>
                <p>The yield for genetic testing varies by the pre-test probability of the disease as determined by the clinical diagnostic criteria. In &#x0201c;definite&#x0201d; FH the yield of genetic testing for identification of a pathogenic variant approaches 95%; in &#x0201c;probable&#x0201d; or &#x0201c;possible&#x0201d; FH the yield is lower (~70%) [<xref ref-type="bibr" rid="hyperchol.REF.motazacker.2012.1360">Motazacker et al 2012</xref>, <xref ref-type="bibr" rid="hyperchol.REF.awan.2013.218">Awan et al 2013</xref>].</p>
              </fn>
              <fn id="hyperchol.TF.1.3">
                <label>3. </label>
                <p>See <xref ref-type="sec" rid="hyperchol.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
              </fn>
              <fn id="hyperchol.TF.1.4">
                <label>4. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="hyperchol.TF.1.5">
                <label>5. </label>
                <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
              </fn>
              <fn id="hyperchol.TF.1.6">
                <label>6. </label>
                <p>
                  <xref ref-type="bibr" rid="hyperchol.REF.huang.1989.11394">Huang et al [1989]</xref>
                </p>
              </fn>
              <fn id="hyperchol.TF.1.7">
                <label>7. </label>
                <p>The majority of pathogenic variants in <italic toggle="yes">LDLR</italic> are detectable by sequence analysis, including those in the regulatory region (the majority occurring within 200 bp upstream of the initiation codon) if that region is targeted for sequencing [<xref ref-type="bibr" rid="hyperchol.REF.dedoussis.2004.443">Dedoussis et al 2004</xref>].</p>
              </fn>
              <fn id="hyperchol.TF.1.8">
                <label>8. </label>
                <p><xref ref-type="bibr" rid="hyperchol.REF.horsthemke.1987.144">Horsthemke et al [1987]</xref>, <xref ref-type="bibr" rid="hyperchol.REF.dedoussis.2004.443">Dedoussis et al [2004]</xref>, <xref ref-type="bibr" rid="hyperchol.REF.bertolini.2013.342">Bertolini et al [2013]</xref></p>
              </fn>
              <fn id="hyperchol.TF.1.9">
                <label>9. </label>
                <p>No deletions or duplications involving <italic toggle="yes">PCSK9</italic> have been reported to cause familial hypercholesterolemia [<xref ref-type="bibr" rid="hyperchol.REF.de_castroor_s.2010.53">De Castro-Or&#x000f3;s et al 2010</xref>].</p>
              </fn>
              <fn id="hyperchol.TF.1.10">
                <label>10. </label>
                <p>
                  <xref ref-type="bibr" rid="hyperchol.REF.de_castroor_s.2010.53">De Castro-Or&#x000f3;s et al [2010]</xref>
                </p>
              </fn>
              <fn id="hyperchol.TF.1.11">
                <label>11. </label>
                <p>It has been suggested that a polygenic etiology is most likely in the majority of individuals with a clinical diagnosis of FH in whom no pathogenic variant in one of the three known genes can be identified. This suggestion is based on the presence in these individuals of a greater than average number of common LDL-C-raising variants (i.e., a high &#x0201c;LDL-SNP score&#x0201d;) [<xref ref-type="bibr" rid="hyperchol.REF.talmud.2013.1293">Talmud et al 2013</xref>].</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Test characteristics.</bold> See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nature.com/ejhg/journal/v22/n7/full/ejhg2013271a.html">Clinical Utility Gene Card</ext-link> [<xref ref-type="bibr" rid="hyperchol.REF.kassner.2014">Kassner et al 2014</xref>] for information on test characteristics including sensitivity and specificity.</p>
        </sec>
      </sec>
      <sec id="hyperchol.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="hyperchol.Clinical_Description">
          <title>Clinical Description</title>
          <sec id="hyperchol.Familial_Hypercholesterolemia">
            <title>Familial Hypercholesterolemia (FH)</title>
            <p><bold>Coronary artery disease (CAD) and cardiovascular disease (CVD).</bold> Elevated LDL cholesterol (LDL-C) leads to atherosclerotic plaque deposition in the coronary arteries and proximal aorta at an early age, leading over time to an increased risk for cardiovascular disease (CVD), which by definition includes coronary artery disease (CAD) (manifest as angina and myocardial infarction) and stroke [<xref ref-type="bibr" rid="hyperchol.REF.scientific_steering_committee.1991.893">Scientific Steering Committee 1991</xref>, <xref ref-type="bibr" rid="hyperchol.REF.versmissen.2008.a2423">Versmissen et al 2008</xref>, <xref ref-type="bibr" rid="hyperchol.REF.elis.2011.223">Elis et al 2011</xref>, <xref ref-type="bibr" rid="hyperchol.REF.raal.2012.262">Raal &#x00026; Santos 2012</xref>]. In FH, CAD is the more common cardiovascular disease; stroke occurs more rarely and some evidence suggests that the risk for stroke may not be greater than in the general population [<xref ref-type="bibr" rid="hyperchol.REF.huxley.2003.22">Huxley et al 2003</xref>].</p>
            <p>All individuals with FH should be considered &#x0201c;high risk&#x0201d; (i.e., increased ~20-fold) for CAD. Recent data suggest that individuals with an LDL-C &#x0003e;190 mg/dL (&#x0003e;4.9 mmol/L) and a pathogenic variant in one of the genes listed in <xref ref-type="table" rid="hyperchol.T.molecular_genetic_testing_us">Table 1</xref> have a 22-fold increased risk for CAD while those without a pathogenic variant have a sixfold increased risk for CAD over the general population [<xref ref-type="bibr" rid="hyperchol.REF.khera.2016.2578">Khera et al 2016</xref>].</p>
            <p>Natural history studies from the pre-statin era suggest that untreated men are at 50% risk for a fatal or non-fatal coronary event by age 50 years; untreated women are at 30% risk by age 60 years [<xref ref-type="bibr" rid="hyperchol.REF.slack.1969.1380">Slack 1969</xref>, <xref ref-type="bibr" rid="hyperchol.REF.stone.1974.476">Stone et al 1974</xref>, <xref ref-type="bibr" rid="hyperchol.REF.civeira.2004.55">Civeira 2004</xref>, <xref ref-type="bibr" rid="hyperchol.REF.goldberg.2011">Goldberg et al 2011</xref>, <xref ref-type="bibr" rid="hyperchol.REF.reiner.2011.1769">Reiner et al 2011</xref>]. See <xref ref-type="fig" rid="hyperchol.F1">Figure 1</xref>. Of note, standard Framingham or other risk classification schemes are not applicable to persons with FH [<xref ref-type="bibr" rid="hyperchol.REF.goldberg.2011">Goldberg et al 2011</xref>, <xref ref-type="bibr" rid="hyperchol.REF.reiner.2011.1769">Reiner et al 2011</xref>, <xref ref-type="bibr" rid="hyperchol.REF.nordestgaard.2013.3478">Nordestgaard et al 2013</xref>].</p>
            <p>Lipid-lowering therapy with statin-based regimens (see <bold>Management</bold>, <xref ref-type="sec" rid="hyperchol.Treatment_of_Manifestations">Treatment of Manifestations</xref>) significantly increases survival [<xref ref-type="bibr" rid="hyperchol.REF.nordestgaard.2013.3478">Nordestgaard et al 2013</xref>, <xref ref-type="bibr" rid="hyperchol.REF.vuorio.2013.315">Vuorio et al 2013</xref>] and reduces morbidity [<xref ref-type="bibr" rid="hyperchol.REF.versmissen.2008.a2423">Versmissen et al 2008</xref>, <xref ref-type="bibr" rid="hyperchol.REF.elis.2011.223">Elis et al 2011</xref>]. Additional medications such as ezetimibe, bile acid binding resins, or PCSK9 inhibiters are often necessary to achieve optimal LDL-C reduction [<xref ref-type="bibr" rid="hyperchol.REF.gidding.2015.2167">Gidding et al 2015</xref>].</p>
            <p>Data from the CASCADE-FH registry reveals that upwards of 61% of adults with FH have at least one modifiable cardiovascular risk factor. Coronary heart disease was reported in 47% of men with FH, with a median age of onset of 47 years. Coronary heart disease was reported in 29% of women with FH, with a median age of onset of 55 years. A high-dose statin was being taken by 42% of individuals with FH, 33% of individuals were on a low-dose statin, and 25% of individuals were not taking a statin. The most common reasons for lack of statin use included intolerance or allergy (60%), patient preference (11%), physician preference (11%), pregnancy (3%), cost (1%), and clinical trial participation (1%). Twenty-five percent of treated individuals had an LDL-C below 100 mg/dL and 41% of individuals achieved a 50% or greater reduction in LDL-C from untreated values [deGoma et al 2016].</p>
            <p><bold>Xanthomas</bold> are patches of yellowish cholesterol buildup in particular areas of the body as a result of extremely high levels of LDL-C. Xanthomas may worsen with age in persons who are not treated. In persons treated with LDL-C-lowering therapy, the xanthomas can become smaller. Common locations:</p>
            <list list-type="bullet">
              <list-item>
                <p>Xanthomas often occur around the eyelids (xanthelasma palpebrarum or more commonly just xanthelasma) [<xref ref-type="bibr" rid="hyperchol.REF.dey.2013">Dey et al 2013</xref>].</p>
              </list-item>
              <list-item>
                <p>Tendonous xanthomas can occur in the elbows, hands, knees, and feet, particularly the Achilles tendon [<xref ref-type="bibr" rid="hyperchol.REF.tsouli.2005.236">Tsouli et al 2005</xref>, <xref ref-type="bibr" rid="hyperchol.REF.elis.2011.223">Elis et al 2011</xref>]. These are historically described in 30%-50% of persons with FH, although more recent studies show a lower prevalence likely due to widespread statin use [<xref ref-type="bibr" rid="hyperchol.REF.perez_de_isla.2016.1278">Perez de Isla et al 2016</xref>].</p>
              </list-item>
              <list-item>
                <p>Interdigital xanthomas (between the fingers) occur in individuals with homozygous FH.</p>
              </list-item>
            </list>
            <p><bold>Corneal arcus</bold> (white, gray, or blue opaque ring in the corneal margin). Because corneal arcus becomes increasingly common in the general population with age, it is only diagnostic in younger individuals, particularly before age 45 years.</p>
          </sec>
          <sec id="hyperchol.Homozygous_Familial_Hyperchole">
            <title>Homozygous Familial Hypercholesterolemia (HoFH)</title>
            <p>Homozygous familial hypercholesterolemia refers to familial hypercholesterolemia resulting from biallelic (homozygous or compound heterozygous) pathogenic variants in one of the genes listed in <xref ref-type="table" rid="hyperchol.T.molecular_genetic_testing_us">Table 1</xref> (<italic toggle="yes">APOB, LDLR,</italic> and <italic toggle="yes">PCSK9</italic>). The prevalence of HoFH, estimated at 1:160,000 to 1:250,000, is much lower than FH [<xref ref-type="bibr" rid="hyperchol.REF.nordestgaard.2013.3478">Nordestgaard et al 2013</xref>, <xref ref-type="bibr" rid="hyperchol.REF.cuchel.2014.2146">Cuchel et al 2014</xref>].</p>
            <p>In adults with HoFH, untreated LDL-C levels are generally, but not always, &#x0003e;500 mg/dL (&#x0003e;13 mmol/L). Levels can be lower in children or in treated individuals. Thus, LDL-C levels are not sufficient to confirm a diagnosis [<xref ref-type="bibr" rid="hyperchol.REF.cuchel.2014.2146">Cuchel et al 2014</xref>].</p>
            <p>In addition to xanthomas around the eyelids and tendonous xanthomas, individuals with HoFH can have interdigital xanthomas (between the fingers).</p>
            <p>The natural history of HoFH differs from that of FH. Most individuals with HoFH experience severe CAD by their mid-20s. The rate of either death or coronary bypass surgery by the teenage years is high [<xref ref-type="bibr" rid="hyperchol.REF.raal.2012.262">Raal &#x00026; Santos 2012</xref>]. Severe aortic stenosis is also common [<xref ref-type="bibr" rid="hyperchol.REF.raal.2012.262">Raal &#x00026; Santos 2012</xref>, <xref ref-type="bibr" rid="hyperchol.REF.raal.2016a.238">Raal et al 2016a</xref>, <xref ref-type="bibr" rid="hyperchol.REF.raal.2016b.1458">Raal et al 2016b</xref>].</p>
            <p>Statins are often relatively ineffective in the treatment of HoFH because their efficacy largely depends on the upregulation of functional LDL receptors in the liver. In individuals with HoFH, activity of both copies of the LDL receptor are absent or greatly reduced [<xref ref-type="bibr" rid="hyperchol.REF.raal.2012.262">Raal &#x00026; Santos 2012</xref>]; therefore, therapy for HoFH often requires LDL apheresis in addition to the use of multiple other medications (see <bold>Management</bold>, <xref ref-type="sec" rid="hyperchol.Treatment_of_Manifestations">Treatment of Manifestations</xref>) [<xref ref-type="bibr" rid="hyperchol.REF.raal.2010.998">Raal et al 2010</xref>, <xref ref-type="bibr" rid="hyperchol.REF.raal.2013.7">Raal 2013</xref>, <xref ref-type="bibr" rid="hyperchol.REF.cuchel.2014.2146">Cuchel et al 2014</xref>].</p>
          </sec>
        </sec>
        <sec id="hyperchol.Phenotype_Correlations_by_Gene">
          <title>Phenotype Correlations by Gene</title>
          <p><bold><italic toggle="yes">APOB</italic>.</bold> FH caused by a heterozygous <italic toggle="yes">APOB</italic> pathogenic variant is reported to be less severe than FH caused by a heterozygous pathogenic variant in <italic toggle="yes">LDLR</italic> or <italic toggle="yes">PCSK9</italic> [<xref ref-type="bibr" rid="hyperchol.REF.hopkins.2011">Hopkins et al 2011</xref>].</p>
        </sec>
        <sec id="hyperchol.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p><bold><italic toggle="yes">LDLR.</italic></bold> Complete loss-of-function variants in <italic toggle="yes">LDLR</italic> generally lead to more severe disease due to higher LDL-C levels [<xref ref-type="bibr" rid="hyperchol.REF.khera.2016.2578">Khera et al 2016</xref>]. Partial loss-of-function variants in <italic toggle="yes">LDLR</italic> result in less severe disease due to lower LDL-C levels.</p>
        </sec>
        <sec id="hyperchol.Penetrance">
          <title>Penetrance</title>
          <p><bold><italic toggle="yes">APOB.</italic></bold> Penetrance for FH can be incomplete in persons with a heterozygous <italic toggle="yes">APOB</italic> pathogenic variant [<xref ref-type="bibr" rid="hyperchol.REF.fahed.2011.23">Fahed &#x00026; Nemer 2011</xref>].</p>
          <p><bold><italic toggle="yes">LDLR.</italic></bold> Recent findings suggest that only 73% of individuals with a heterozygous <italic toggle="yes">LDLR</italic> pathogenic variant have an LDL level &#x0003e;130 mg/dL, suggesting lower penetrance than previously proposed [<xref ref-type="bibr" rid="hyperchol.REF.khera.2016.2578">Khera et al 2016</xref>].</p>
          <p>
            <bold>
              <italic toggle="yes">PCSK9</italic>
            </bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Penetrance is approximately 90% in persons heterozygous for the <xref ref-type="table" rid="hyperchol.T.pcsk9_selected_pathogenic_va">c.381T&#x0003e;A</xref> (p.Ser127Arg) pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>Penetrance in persons heterozygous for the <xref ref-type="table" rid="hyperchol.T.pcsk9_selected_pathogenic_va">p.Asp374Tyr</xref> pathogenic variant is high, with FH manifesting at a young age [<xref ref-type="bibr" rid="hyperchol.REF.naoumova.2005.2654">Naoumova et al 2005</xref>].</p>
            </list-item>
            <list-item>
              <p>Penetrance for other heterozygous <italic toggle="yes">PCSK9</italic> pathogenic variants remains largely unknown [<xref ref-type="bibr" rid="hyperchol.REF.cariou.2011.258">Cariou et al 2011</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="hyperchol.Prevalence">
          <title>Prevalence</title>
          <p>The prevalence of FH in the general population has traditionally been cited as 1:500. However, emerging data suggest that the prevalence of FH is higher in white/European populations, perhaps as common as 1:200 [<xref ref-type="bibr" rid="hyperchol.REF.benn.2012.3956">Benn et al 2012</xref>, <xref ref-type="bibr" rid="hyperchol.REF.nordestgaard.2013.3478">Nordestgaard et al 2013</xref>].</p>
          <p>FH is more common (due to founder effects) in several populations (<xref ref-type="table" rid="hyperchol.T.prevalence_of_fh_in_select_p">Table 2</xref>). Of note, data are limited on prevalence of FH in most African and South Asian/Indian populations.</p>
          <table-wrap id="hyperchol.T.prevalence_of_fh_in_select_p" orientation="portrait" position="anchor">
            <label>Table 2. </label>
            <caption>
              <p>Prevalence of FH in Select Populations</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_hyperchol.T.prevalence_of_fh_in_select_p_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Population</th>
                  <th id="hd_h_hyperchol.T.prevalence_of_fh_in_select_p_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Prevalence</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_hyperchol.T.prevalence_of_fh_in_select_p_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">General population</td>
                  <td headers="hd_h_hyperchol.T.prevalence_of_fh_in_select_p_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1:250</td>
                </tr>
                <tr>
                  <td headers="hd_h_hyperchol.T.prevalence_of_fh_in_select_p_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">French Canadian&#x000a0;<sup>1</sup></td>
                  <td headers="hd_h_hyperchol.T.prevalence_of_fh_in_select_p_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1:270</td>
                </tr>
                <tr>
                  <td headers="hd_h_hyperchol.T.prevalence_of_fh_in_select_p_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Old Order Amish&#x000a0;<sup>2</sup></td>
                  <td headers="hd_h_hyperchol.T.prevalence_of_fh_in_select_p_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1:10</td>
                </tr>
                <tr>
                  <td headers="hd_h_hyperchol.T.prevalence_of_fh_in_select_p_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Christian Lebanese</td>
                  <td headers="hd_h_hyperchol.T.prevalence_of_fh_in_select_p_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1:85</td>
                </tr>
                <tr>
                  <td headers="hd_h_hyperchol.T.prevalence_of_fh_in_select_p_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Tunisia</td>
                  <td headers="hd_h_hyperchol.T.prevalence_of_fh_in_select_p_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1:165</td>
                </tr>
                <tr>
                  <td headers="hd_h_hyperchol.T.prevalence_of_fh_in_select_p_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">South African Afrikaners</td>
                  <td headers="hd_h_hyperchol.T.prevalence_of_fh_in_select_p_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1:72 to 1:100</td>
                </tr>
                <tr>
                  <td headers="hd_h_hyperchol.T.prevalence_of_fh_in_select_p_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">South African Ashkenazi Jews</td>
                  <td headers="hd_h_hyperchol.T.prevalence_of_fh_in_select_p_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1:67</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>
                  <xref ref-type="bibr" rid="hyperchol.REF.austin.2004.407">Austin et al [2004]</xref>
                </p>
              </fn>
              <fn id="hyperchol.TF.2.1">
                <label>1. </label>
                <p>A common &#x0003e;15-kb (60% of alleles) and an ~5-kb (5% of alleles) <italic toggle="yes">LDLR</italic> deletion results in a significant increase in LDL-C [<xref ref-type="bibr" rid="hyperchol.REF.simard.2004.202">Simard et al 2004</xref>].</p>
              </fn>
              <fn id="hyperchol.TF.2.2">
                <label>2. </label>
                <p>Amish individuals heterozygous for <italic toggle="yes">APOB</italic> p.Arg3500Gln (the most common pathogenic variant in the Amish community) have average LDL-C levels below the suggested minimum for a diagnosis of FH. However, coronary artery calcification and atherosclerosis still occurred in heterozygous Amish individuals with lower average LDL-C levels [<xref ref-type="bibr" rid="hyperchol.REF.andersen.2016.443">Andersen et al 2016</xref>].</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
      </sec>
      <sec id="hyperchol.Genetically_Related_Allelic_Di">
        <title>Genetically Related (Allelic) Disorders</title>
        <p><bold><italic toggle="yes">APOB.</italic></bold> Homozygous or heterozygous loss-of-function pathogenic variants in <italic toggle="yes">APOB</italic> cause familial hypobetalipoproteinemia (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/615558">OMIM</ext-link>) characterized by extremely low levels of LDL-C [<xref ref-type="bibr" rid="hyperchol.REF.burnett.2012.20">Burnett et al 2012</xref>].</p>
        <p><bold><italic toggle="yes">LDLR.</italic></bold> No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with pathogenic variants in <italic toggle="yes">LDLR</italic>.</p>
        <p><bold><italic toggle="yes">PCSK9.</italic></bold> Heterozygous or homozygous loss-of-function pathogenic variants in <italic toggle="yes">PCSK9</italic> cause hypocholesterolemia (reduced blood cholesterol levels). Loss-of-function pathogenic variants lead to an increase in the number of low-density lipoprotein receptors on the surface of liver cells, resulting in quicker than usual removal of LDL-C from the blood and, hence, a reduced risk for coronary heart disease [<xref ref-type="bibr" rid="hyperchol.REF.cohen.2006.1264">Cohen et al 2006</xref>, <xref ref-type="bibr" rid="hyperchol.REF.pandit.2008.1333">Pandit et al 2008</xref>].</p>
      </sec>
      <sec id="hyperchol.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Conditions with <bold>clinical findings</bold> similar to those of familial hypercholesterolemia (FH) include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>27-hydroxylase deficiency (</bold><related-object link-type="booklink" source-id="gene" document-id="ctx" document-type="chapter"><bold>cerebrotendonous xanthomatosis</bold></related-object><bold>),</bold> which is characterized by xanthomas. Distinguishing features are normal LDL cholesterol (LDL-C) levels and the presence of dementia, ataxia, and cataracts. Biallelic pathogenic variants in <italic toggle="yes">CYP27A1</italic> are causative; inheritance is autosomal recessive.</p>
          </list-item>
          <list-item>
            <p><bold>Hyperlipoproteinemia type III (familial dysbetalipoproteinemia)</bold> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/107741">OMIM</ext-link>). Clinical features may include xanthomas. Hyperlipoproteinemia type III is caused by biallelic pathogenic variants in <italic toggle="yes">APOE.</italic> Inheritance is autosomal recessive [<xref ref-type="bibr" rid="hyperchol.REF.fung.2011">Fung et al 2011</xref>].</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="stsl" document-type="chapter"><bold>Sitosterolemia</bold></related-object> (phytosterolemia), which is distinguished by normal or only mildly elevated LDL-C levels. Biallelic pathogenic variants in either <italic toggle="yes">ABCG5</italic> or <italic toggle="yes">ABCG8</italic> are causative; inheritance is autosomal recessive.</p>
          </list-item>
          <list-item>
            <p><bold>Polygenic hypercholesterolemia.</bold>
<xref ref-type="bibr" rid="hyperchol.REF.talmud.2013.1293">Talmud et al [2013]</xref> found that individuals with features suggestive of FH in whom an <italic toggle="yes">LDLR</italic>, <italic toggle="yes">PCSK9</italic>, or <italic toggle="yes">APOB</italic> pathogenic variant was not identified are in fact likely to have polygenic hypercholesterolemia. In this case, individuals have a high genetic risk score for more common LDL-C raising alleles.</p>
          </list-item>
          <list-item>
            <p><bold>Extremely elevated lipoprotein a</bold>
<bold>(Lpa)</bold> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/152200">OMIM</ext-link>). Individuals with very high Lpa often have a personal and family history of early-onset CAD and very elevated LDL-C levels [<xref ref-type="bibr" rid="hyperchol.REF.langsted.2016.577">Langsted et al 2016</xref>]. High Lpa levels are also widely appreciated to synergistically increase risk in individuals with FH. The disorder is inherited in an autosomal dominant manner and caused by variants in the number of kringle IV type 2 repeats in <italic toggle="yes">LPL</italic>.</p>
          </list-item>
        </list>
        <p>Conditions with <bold>laboratory findings</bold> similar to those of FH include the following [<xref ref-type="bibr" rid="hyperchol.REF.goldberg.2011">Goldberg et al 2011</xref>]:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Hypercholesterolemia</bold> secondary to obesity, diabetes mellitus, hypothyroidism, drugs (e.g., steroids), or kidney disease. Inheritance follows a non-Mendelian pattern.</p>
          </list-item>
          <list-item>
            <p><bold>Autosomal recessive hypercholesterolemia</bold> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/603813">OMIM</ext-link>) caused by biallelic pathogenic variants in <italic toggle="yes">LDLRAP1</italic>. Persons with biallelic pathogenic variants have LDL-C &#x0003e;400 mg/dL (&#x0003e;10 mmol/L), whereas heterozygotes have normal LDL-C levels.</p>
          </list-item>
          <list-item>
            <p><bold>Familial combined hyperlipidemia</bold>
<bold>(FCHL)</bold> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry144250">OMIM</ext-link>), associated with elevated LDL-C and triglycerides. FCHL is genetically heterogeneous. Only 10%-20% of individuals show elevated levels in childhood (usually in the form of hypertriglyceridemia). FCHL is inherited in an autosomal dominant manner and caused by pathogenic variants in <italic toggle="yes">LPL</italic> [<xref ref-type="bibr" rid="hyperchol.REF.brahm.2016.131">Brahm &#x00026; Hegele 2016</xref>]. Additional loci have been mapped to <italic toggle="yes">APOB</italic> and <italic toggle="yes">USF1</italic> in a minority of families [<xref ref-type="bibr" rid="hyperchol.REF.naukkarinen.2006.285">Naukkarinen et al 2006</xref>, <xref ref-type="bibr" rid="hyperchol.REF.hegele.2009.4189">Hegele et al 2009</xref>].</p>
          </list-item>
        </list>
      </sec>
      <sec id="hyperchol.Management">
        <title>Management</title>
        <sec id="hyperchol.Evaluations_Following_Initial">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs of an individual diagnosed with familial hypercholesterolemia (FH) the following evaluations are recommended in adults and children:</p>
          <list list-type="bullet">
            <list-item>
              <p>Measurement of pre-treatment lipid values and lipoprotein(a) levels when possible</p>
            </list-item>
            <list-item>
              <p>Exclusion of concurrent illnesses (kidney disease, acute myocardial infarction, infection) that can affect lipid values</p>
            </list-item>
            <list-item>
              <p>Lipid panel including total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides</p>
            </list-item>
            <list-item>
              <p>Consultation with a lipid specialist or clinician with expertise in FH</p>
            </list-item>
            <list-item>
              <p>Recommended in some guidelines: noninvasive imaging modalities in children (e.g., measurement of carotid intima-media thickness) to help inform treatment decisions [<xref ref-type="bibr" rid="hyperchol.REF.martin.2013">Martin et al 2013</xref>]</p>
            </list-item>
            <list-item>
              <p>Consultation with a clinical geneticist and/or genetic counselor</p>
            </list-item>
          </list>
        </sec>
        <sec id="hyperchol.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <sec id="hyperchol.Adults_with_FH">
            <title>Adults with FH</title>
            <p>All individuals with FH should be considered &#x0201c;high risk&#x0201d; for coronary artery disease (CAD) and should be treated actively to lower cholesterol levels. Note that standard Framingham or other risk classification schemes are not applicable [<xref ref-type="bibr" rid="hyperchol.REF.goldberg.2011">Goldberg et al 2011</xref>, <xref ref-type="bibr" rid="hyperchol.REF.hopkins.2011">Hopkins et al 2011</xref>, <xref ref-type="bibr" rid="hyperchol.REF.stone.2014.2889">Stone et al 2014</xref>]. The most current recommendations (summarized here) for the management of FH used in the United States are from the American Heart Association [<xref ref-type="bibr" rid="hyperchol.REF.gidding.2015.2167">Gidding et al 2015</xref>] (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://circ.ahajournals.org/content/132/22/2167.long">full text</ext-link>) and largely reflect earlier recommendations from the National Lipid Association (NLA).</p>
            <p>For adults, treatment should begin as soon as possible after diagnosis. All adults with FH require diet/lifestyle management, and almost without exception will also require cholesterol-lowering drug therapy.</p>
            <list list-type="bullet">
              <list-item>
                <p>Risk factors (e.g., smoking, diabetes mellitus, hypertension) are the same in FH as in the general population; aggressive management is required to reduce CAD risk, with special attention to smoking cessation.</p>
              </list-item>
              <list-item>
                <p>Regular physical activity, a healthy diet (reduce saturated fat intake, increase intake of soluble fiber to 10-20 g/day), and weight control should be emphasized.</p>
              </list-item>
              <list-item>
                <p>Blood pressure should be treated to 140/90mm Hg (or 130/80 mm Hg in those with diabetes mellitus).</p>
              </list-item>
              <list-item>
                <p>Low-dose aspirin (75-81 mg/day) should be considered in those at high risk for CAD or stroke.</p>
              </list-item>
              <list-item>
                <p>Consider referral to a lipid specialist with expertise in FH if LDL-C concentrations are not reduced with maximal medical therapy (Note: Although it has not been specified, this recommendation generally pertains to LDL-C levels that cannot be reduced by &#x02265;50% with maximal medical therapy over a 6-month period.)</p>
              </list-item>
              <list-item>
                <p>Testing of first-degree and second-degree relatives should be recommended to all individuals with FH (see <xref ref-type="sec" rid="hyperchol.Evaluation_of_Relatives_at_Ris">Evaluation of Relatives at Risk</xref>).</p>
              </list-item>
              <list-item>
                <p>For adults with FH age 20 years or older, treatment with statins should be initiated to reduce the LDL-C level &#x02265;50% or to &#x0003c;100 mg/dL (&#x0003c;2.6 mmol/L) [<xref ref-type="bibr" rid="hyperchol.REF.hopkins.2011">Hopkins et al 2011</xref>, <xref ref-type="bibr" rid="hyperchol.REF.nordestgaard.2013.3478">Nordestgaard et al 2013</xref>]. Many guidelines suggest a target LDL-C of &#x0003c;100 mg/dL even in those without known CAD as individuals with FH have had a lifelong burden of high LDL-C [<xref ref-type="bibr" rid="hyperchol.REF.gidding.2015.2167">Gidding et al 2015</xref>].</p>
              </list-item>
            </list>
            <p><bold>For persons with FH with any of the following CAD risk factors,</bold> drug treatment may need to be intensified (see *Note) to achieve more aggressive treatment goals (LDL-C &#x0003c;100 mg/dL [&#x0003c;2.6 mmol/L] and non-HDL-C &#x0003c;130 mg/dL [&#x0003c;3.4 mmol/L]). Risk factors:</p>
            <list list-type="bullet">
              <list-item>
                <p>Clinically evident CAD or other atherosclerotic cardiovascular disease; the goal is LDL-C level of &#x0003c;70 mg/dL (&#x0003c;1.8 mmol/L)</p>
              </list-item>
              <list-item>
                <p>Diabetes mellitus or metabolic syndrome</p>
              </list-item>
              <list-item>
                <p>Family history of very early CAD (men age &#x0003c;45 years; women age &#x0003c;55 years)</p>
              </list-item>
              <list-item>
                <p>Current smoking</p>
              </list-item>
              <list-item>
                <p>High lipoprotein(a) (&#x02265;50 mg/dL [&#x02265;1.3 mmol/L] using an isoform insensitive assay)</p>
              </list-item>
            </list>
            <p>The second-line agent for individuals with FH who do not achieve acceptable LDL-C levels is generally ezetimibe. Treatment options for intensification of therapy after ezetimibe or for those intolerant of statins include: bile acid sequestrants and/or PCSK9 inhibitors. Although niacin has been used as an adjunctive therapy in individuals with FH, given recent data, niacin is generally not favored before the other options have been exhausted [<xref ref-type="bibr" rid="hyperchol.REF.guyton.2013.1580">Guyton et al 2013</xref>, <xref ref-type="bibr" rid="hyperchol.REF28">FDA 2016</xref>] (see <xref ref-type="table" rid="hyperchol.T.current_recommended_drug_the">Table 3</xref>).</p>
            <p><bold>In persons with FH without any of the CAD risk factors</bold> listed above, intensification of drug therapy (see *Note) should be strongly considered if 50% reduction in LDL-C is not achieved after six months on maximum statin therapy. For adults, some guidelines call for intensification of treatment if the goal LDL-C of &#x0003c;100 mg/dL (&#x0003c;2.6 mmol/L) is not achieved [<xref ref-type="bibr" rid="hyperchol.REF.nordestgaard.2013.3478">Nordestgaard et al 2013</xref>].</p>
            <p>*Note: (1) The lipid-lowering therapy should initially be statin-based with titration of doses every few months in order to use the highest tolerated dose of a potent statin, followed by addition of other drugs if the targeted LDL-C level is not achieved. (2) The potential benefit of multi-drug regimens should be weighed against the increased cost and potential for adverse effects and decreased adherence.</p>
            <table-wrap id="hyperchol.T.current_recommended_drug_the" orientation="portrait" position="anchor">
              <label>Table 3. </label>
              <caption>
                <p>Current Recommended Drug Therapies for Adults with FH</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Class</th>
                    <th id="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Primary (1<sup>O</sup>) and Secondary (2<sup>O</sup>) Mechanism of Action</th>
                    <th id="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">LDL-Lowering Response</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Statins</td>
                    <td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">&#x02191; LDLR activity (1<sup>O</sup>)</td>
                    <td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;35%&#x000a0;<sup>1,&#x000a0;2</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Cholesterol absorption inhibitors (ezetimibe)</td>
                    <td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">&#x02193; Cholesterol absorption (1<sup>O</sup>)<break/>&#x02191; LDLR activity (2<sup>O</sup>)</td>
                    <td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">15%&#x000a0;<sup>1,&#x000a0;3</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Mipomersen (APOB antisense)&#x000a0;<sup>4</sup></td>
                    <td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Blocks APOB production in the liver</td>
                    <td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">50%&#x000a0;<sup>5</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">MTP inhibitor<break/>(lomitapide)&#x000a0;<sup>4</sup></td>
                    <td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">&#x02193; microsomal triglyceride transfer protein activity (1<sup>O</sup>)<break/>inhibition of LDL production (2<sup>O</sup>)</td>
                    <td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">50%&#x000a0;<sup>5</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">PCSK9 inhibitors<break/>(alirocumab, evolocumab)</td>
                    <td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">&#x02193; LDL-receptor degradation</td>
                    <td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">50%&#x000a0;<sup>6</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Bile acid sequestrants<break/>(cholestyramine, colesevelam)</td>
                    <td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">&#x02193; Bile acid re-absorption (1<sup>O</sup>)<break/>&#x02191; LDLR activity (2<sup>O</sup>)</td>
                    <td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">15%&#x000a0;<sup>1,&#x000a0;3</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Stanol esters</td>
                    <td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">&#x02193; Cholesterol absorption (1<sup>O</sup>)<break/>&#x02191; LDLR activity (2<sup>O</sup>)</td>
                    <td headers="hd_h_hyperchol.T.current_recommended_drug_the_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">10%&#x000a0;<sup>1,&#x000a0;3</sup></td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn>
                  <p>Some guidelines call for the addition of n-3 polyunsaturated fatty acids or fibrates if triglycerides remain elevated after the LDL-C is controlled.</p>
                </fn>
                <fn id="hyperchol.TF.3.1">
                  <label>1. </label>
                  <p>Often ineffective in HoFH</p>
                </fn>
                <fn id="hyperchol.TF.3.2">
                  <label>2. </label>
                  <p>
                    <xref ref-type="bibr" rid="hyperchol.REF.kastelein.2008.1431">Kastelein et al [2008]</xref>
                  </p>
                </fn>
                <fn id="hyperchol.TF.3.3">
                  <label>3. </label>
                  <p>
                    <xref ref-type="bibr" rid="hyperchol.REF.rader.2003.1795">Rader et al [2003]</xref>
                  </p>
                </fn>
                <fn id="hyperchol.TF.3.4">
                  <label>4. </label>
                  <p>Approved only for adults with HoFH</p>
                </fn>
                <fn id="hyperchol.TF.3.5">
                  <label>5. </label>
                  <p>
                    <xref ref-type="bibr" rid="hyperchol.REF.cuchel.2014.2146">Cuchel et al [2014]</xref>
                  </p>
                </fn>
                <fn id="hyperchol.TF.3.6">
                  <label>6. </label>
                  <p>
                    <xref ref-type="bibr" rid="hyperchol.REF.raal.2012.262">Raal &#x00026; Santos [2012]</xref>
                  </p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
          <sec id="hyperchol.Children_with_FH">
            <title>Children with FH</title>
            <p>Guidelines for the management of children and individuals up to age 21 years have been published by the National Heart, Lung, and Blood Institute (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.nhlbi.nih.gov/files/docs/peds_guidelines_sum.pdf">full text</ext-link>). Children should be considered for drug treatment with statin-based regimens when:</p>
            <list list-type="bullet">
              <list-item>
                <p>LDL-C levels are &#x02265;190 mg/dL (&#x02265;4.9 mmol/L).</p>
              </list-item>
              <list-item>
                <p>LDL-C levels are &#x02265;160 mg/dL (&#x02265;4.1 mmol/L) and at least two other risk factors are present.</p>
              </list-item>
            </list>
            <p>US-based guidelines from the NLA (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=16222">full text</ext-link>):</p>
            <list list-type="bullet">
              <list-item>
                <p>Consultation or referral to a lipid specialist is recommended.</p>
              </list-item>
              <list-item>
                <p>Management of diet and physical activity is recommended at an early age.</p>
              </list-item>
              <list-item>
                <p>Statins are the preferred initial pharmacologic treatment in children. Consideration should be given to starting statin treatment at age eight years or older. In special cases, such as children with homozygous FH, drug treatment needs to be initiated prior to age eight years.</p>
              </list-item>
              <list-item>
                <p>The goal of lipid-lowering therapy in children with FH is a &#x02265;50% reduction in LDL-C or LDL-C &#x0003c;130 mg/dL (&#x0003c;3.4 mmol/L). Note: More aggressive lowering of LDL-C levels should be considered for children with additional CAD risk factors (e.g., family history of CAD, high blood pressure, unhealthy diet or exercise behaviors, obesity).</p>
              </list-item>
            </list>
          </sec>
          <sec id="hyperchol.Children_and_Adults_with_Homoz">
            <title>Children and Adults with Homozygous FH (HoFH)</title>
            <p>NLA guidelines for homozygous FH (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=16222">full text</ext-link>):</p>
            <list list-type="bullet">
              <list-item>
                <p>Referral to a lipid specialist is indicated.</p>
              </list-item>
              <list-item>
                <p>Early initiation of therapy and monitoring are recommended.</p>
              </list-item>
              <list-item>
                <p>Multiple drug therapy is usually needed. Several different classes of medications are currently being used to treat HoFH (see <xref ref-type="table" rid="hyperchol.T.current_recommended_drug_the">Table 3</xref>).</p>
              </list-item>
              <list-item>
                <p>Since many cholesterol-lowering medications target the LDL receptor, effectiveness in persons with FH with biallelic loss-of function <italic toggle="yes">LDLR</italic> pathogenic variants can be limited [<xref ref-type="bibr" rid="hyperchol.REF.cuchel.2014.2146">Cuchel et al 2014</xref>]. Statins are often relatively ineffective in the treatment of HoFH because their efficacy largely depends on the upregulation of functional LDL receptors in the liver. In HoFH, both copies of the LDL receptor have absent or greatly reduced activity [<xref ref-type="bibr" rid="hyperchol.REF.raal.2012.262">Raal &#x00026; Santos 2012</xref>].</p>
              </list-item>
              <list-item>
                <p>High-dose statins, ezetimibe, and bile-acid binding resins may be effective in some persons with HoFH, especially those with some residual LDLR activity.</p>
              </list-item>
              <list-item>
                <p>For HoFH, evolocumab is a PCSK9 inhibitor that showed a 40% mean reduction in LDL-C compared with placebo; however, individuals with two loss-of-function variants saw no response [<xref ref-type="bibr" rid="hyperchol.REF.raal.2015.341">Raal et al 2015</xref>]. PCSK9 inhibitors have not been formally approved in children with FH.</p>
              </list-item>
              <list-item>
                <p>HoFH-specific medications (lomitapide and mipomersen) are effective even with complete loss of LDL receptor function and &#x02013; though not formally FDA approved for children &#x02013; should strongly be considered.</p>
              </list-item>
              <list-item>
                <p>Despite these options, many individuals with HoFH (especially those with complete loss of LDL receptor function) will require ongoing LDL apheresis. LDL apheresis (&#x02264;2x/week) is often required starting from a young age. Apheresis can lower LDL-C levels by 80% acutely and 30% chronically (weekly or biweekly). Apheresis is offered at a limited number (~40-50) of centers in the United States; many states do not have an apheresis center.</p>
              </list-item>
              <list-item>
                <p>Liver transplantation is also being used in rare circumstances in some centers [<xref ref-type="bibr" rid="hyperchol.REF.martinez.2016.504">Martinez et al 2016</xref>]</p>
              </list-item>
            </list>
          </sec>
        </sec>
        <sec id="hyperchol.Prevention_of_Primary_Manifest">
          <title>Prevention of Primary Manifestations</title>
          <p>Preventive measures include the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Statin-based therapy with addition of other medications as needed</p>
            </list-item>
            <list-item>
              <p>Reduced intake of saturated fat</p>
            </list-item>
            <list-item>
              <p>Increased intake of soluble fiber to 10-20 g/day</p>
            </list-item>
            <list-item>
              <p>Increased physical activity</p>
            </list-item>
            <list-item>
              <p>Not smoking</p>
            </list-item>
          </list>
        </sec>
        <sec id="hyperchol.Surveillance">
          <title>Surveillance</title>
          <p><bold>Children.</bold> Guidelines for the management of children have been published by multiple national and international organizations [<xref ref-type="bibr" rid="hyperchol.REF.daniels.2008">Daniels et al 2008</xref>, <xref ref-type="bibr" rid="hyperchol.REF.demott.2008">DeMott et al 2008</xref>, <xref ref-type="bibr" rid="hyperchol.REF.descamps.2011">Descamps et al 2011</xref>, <xref ref-type="bibr" rid="hyperchol.REF.martin.2013">Martin et al 2013</xref>] (see <xref ref-type="sec" rid="hyperchol.References">Published Guidelines/Consensus Statements</xref> for full texts).</p>
          <p>A child who has a family history of FH or of premature CAD, who is heterozygous for the FH pathogenic variant in his or her family, or who has an elevated serum cholesterol concentration should have lipid levels checked starting as early as age two years [<xref ref-type="bibr" rid="hyperchol.REF.goldberg.2011">Goldberg et al 2011</xref>]. It is reasonable to check a non-fasting lipid level first and, if borderline, to follow with measurement of LDL-C. Some guidelines state that elevation of two consecutive measures of LDL-C are needed to confirm a diagnosis of FH [<xref ref-type="bibr" rid="hyperchol.REF.martin.2013">Martin et al 2013</xref>].</p>
          <p>An LDL-C level of &#x0003e;130 mg/dL (&#x0003e;3.4 mmol/L) in a child is suspicious for FH and an LDL of &#x0003e;160 mg/dL (&#x0003e;4.1 mmol/L) is relatively specific for FH.</p>
          <p><bold>During treatment, individuals of any age</bold> with:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>FH</bold> should have lipid levels monitored as recommended;</p>
            </list-item>
            <list-item>
              <p><bold>HoFH</bold> should be monitored with various imaging modalities (including echocardiogram, CT angiogram, and cardiac catheterization) as recommended [<xref ref-type="bibr" rid="hyperchol.REF.raal.2012.262">Raal &#x00026; Santos 2012</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="hyperchol.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>The following should be avoided:</p>
          <list list-type="bullet">
            <list-item>
              <p>Smoking</p>
            </list-item>
            <list-item>
              <p>High intake of saturated and trans unsaturated fat</p>
            </list-item>
            <list-item>
              <p>Excessive intake of cholesterol</p>
            </list-item>
            <list-item>
              <p>Sedentary lifestyle</p>
            </list-item>
            <list-item>
              <p>Obesity</p>
            </list-item>
            <list-item>
              <p>Hypertension</p>
            </list-item>
            <list-item>
              <p>Diabetes mellitus</p>
            </list-item>
          </list>
        </sec>
        <sec id="hyperchol.Evaluation_of_Relatives_at_Ris">
          <title>Evaluation of Relatives at Risk</title>
          <p>The CDC has classified FH as a Tier 1 condition indicating a significant benefit from performing family-based cascade screening using cholesterol testing with or without DNA analysis on relatives of affected persons with FH in order to identify previously unknown cases of FH and provide those people with life-saving treatment. Early diagnosis and treatment of relatives at risk for FH can reduce morbidity and mortality [<xref ref-type="bibr" rid="hyperchol.REF.goldberg.2011">Goldberg et al 2011</xref>, <xref ref-type="bibr" rid="hyperchol.REF.ned.2011.rrn1238">Ned &#x00026; Sijbrands 2011</xref>, <xref ref-type="bibr" rid="hyperchol.REF.reiner.2011.1769">Reiner et al 2011</xref>].</p>
          <p>The genetic status of at-risk family members can be clarified by EITHER of the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Molecular genetic testing if the pathogenic variant has been identified in an affected family member</p>
            </list-item>
            <list-item>
              <p>Measurement of LDL-C level. <xref ref-type="table" rid="hyperchol.T.total_and_ldl_cholesterol_le">Table 4</xref> provides age-specific total cholesterol and LDL-C levels [<xref ref-type="bibr" rid="hyperchol.REF.williams.1993.319s">Williams et al 1993</xref>]. Note: Age-specific LDL cut-offs are also available based on more contemporary data from the United Kingdom [<xref ref-type="bibr" rid="hyperchol.REF.starr.2008.791">Starr et al 2008</xref>].</p>
            </list-item>
          </list>
          <table-wrap id="hyperchol.T.total_and_ldl_cholesterol_le" orientation="portrait" position="anchor">
            <label>Table 4. </label>
            <caption>
              <p>Total and LDL Cholesterol Levels in Heterozygotes for FH Based on Degree of Relatedness to an Individual with FH</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_1" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Degree of Relatedness to an Affected Individual</th>
                  <th id="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">First Degree&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Second Degree&#x000a0;<sup>2</sup></th>
                  <th id="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Third Degree&#x000a0;<sup>3</sup></th>
                </tr>
                <tr>
                  <th headers="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_1" id="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_2_1" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Cholesterol Levels</th>
                  <th headers="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_2 hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_3 hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_4" id="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_2_2" valign="middle" colspan="3" align="left" scope="colgroup" rowspan="1">Total Cholesterol (LDL Cholesterol) in mg/dL</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_1 hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_2_1" rowspan="4" valign="middle" align="left" scope="row" colspan="1">
                    <bold>Age</bold>
                  </td>
                  <td headers="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_1 hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;20</td>
                  <td headers="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_2 hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">220 (155)</td>
                  <td headers="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_3 hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">230 (165)</td>
                  <td headers="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_4 hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">240 (170)</td>
                </tr>
                <tr>
                  <td headers="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_1 hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_2_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">20-29</td>
                  <td headers="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_2 hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">240 (170)</td>
                  <td headers="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_3 hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">250 (180)</td>
                  <td headers="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_4 hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">260 (185)</td>
                </tr>
                <tr>
                  <td headers="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_1 hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_2_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">30-39</td>
                  <td headers="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_2 hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">270 (190)</td>
                  <td headers="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_3 hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">280 (200)</td>
                  <td headers="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_4 hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">290 (210)</td>
                </tr>
                <tr>
                  <td headers="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_1 hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_2_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">40+</td>
                  <td headers="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_2 hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">290 (205)</td>
                  <td headers="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_3 hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">300 (215)</td>
                  <td headers="hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_1_4 hd_h_hyperchol.T.total_and_ldl_cholesterol_le_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">310 (225)</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="hyperchol.TF.4.1">
                <label>1. </label>
                <p>A parent, sib, or child. First-degree relatives share about half of their genes.</p>
              </fn>
              <fn id="hyperchol.TF.4.2">
                <label>2. </label>
                <p>An uncle, aunt, nephew, niece, grandparent, grandchild, or half-sib. Second-degree relatives share about one quarter of their genes.</p>
              </fn>
              <fn id="hyperchol.TF.4.3">
                <label>3. </label>
                <p>A first cousin, great-grandparent, or great-grandchild. Third-degree relatives share about one eighth of their genes.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p>Of note, all national and international guidelines for FH call for &#x0201c;cascade testing&#x0201d; of relatives at risk (i.e., systematic testing of first- and second-degree relatives of the index case [proband]). Evidence supports the use of genetic testing in cascade testing algorithms to improve the detection of FH [<xref ref-type="bibr" rid="hyperchol.REF.demott.2008">DeMott et al 2008</xref>, <xref ref-type="bibr" rid="hyperchol.REF.wierzbicki.2008.a1095">Wierzbicki et al 2008</xref>, <xref ref-type="bibr" rid="hyperchol.REF.wald.2016.1628">Wald et al 2016</xref>].</p>
          <p>See <xref ref-type="sec" rid="hyperchol.Related_Genetic_Counseling_Iss">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="hyperchol.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>Statins are contraindicated during pregnancy; women with FH who are considering a pregnancy should be counseled of this risk and statins should be discontinued prior to conception.</p>
          <p>Pregnant women should incorporate all the other recommended lifestyle changes including low saturated and trans unsaturated fat intake, no smoking, and high dietary soluble fiber intake (see <xref ref-type="sec" rid="hyperchol.AgentsCircumstances_to_Avoid">Agents/Circumstances to Avoid</xref>).</p>
          <p><bold>Pharmacologic treatment</bold>
<bold>during pregnancy</bold></p>
          <list list-type="bullet">
            <list-item>
              <p>Statins are contraindicated in pregnancy due to concerns for teratogenicity. The use of statins during human pregnancy has not definitively been associated with adverse fetal outcome; however, the role of cholesterol in embryologic development has led to theoretic concerns about the effect of these medications on a developing fetus and a recommendation that alternative medications be considered during pregnancy and lactation. Nursing mothers should not take statins.</p>
            </list-item>
            <list-item>
              <p>Bile acid binding resins (colesevelam, cholestyramine) are generally considered safe (Class B for pregnancy). Based primarily on animal studies, cholestyramine use during pregnancy has not been associated with an increased risk of fetal anomalies. However, use of cholestyramine could theoretically cause depletion of maternal fat-soluble vitamins, including vitamin K.</p>
            </list-item>
            <list-item>
              <p>LDL apheresis is also occasionally used.</p>
            </list-item>
            <list-item>
              <p>Regarding other agents:</p>
              <list list-type="bullet">
                <list-item>
                  <p>PCSK9 inhibitors. Use during pregnancy has not been well studied.</p>
                </list-item>
                <list-item>
                  <p>Ezetimibe. Use during human pregnancy has not been well studied.</p>
                </list-item>
                <list-item>
                  <p>Niacin. The use of pharmacologic doses of niacin, an essential vitamin, has not been studied in human pregnancy. The recommended upper limit of niacin intake during pregnancy is 30-35 mgs/day; higher doses have been associated with toxicity.</p>
                </list-item>
              </list>
            </list-item>
          </list>
        </sec>
        <sec id="hyperchol.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>CAD outcome trials of PCSK9 inhibitors are currently underway.</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="hyperchol.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="hyperchol.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Heterozygous familial hypercholesterolemia (FH, HeFH) and homozygous familial hypercholesterolemia (HoFH) are inherited in an autosomal dominant manner.</p>
        </sec>
        <sec id="hyperchol.Risk_to_Family_Members__Hetero">
          <title>Risk to Family Members &#x02014; Heterozygous Familial Hypercholesterolemia (FH)</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Almost all individuals diagnosed with FH have an affected parent.</p>
            </list-item>
            <list-item>
              <p>A proband with FH may have the disorder as the result of a <italic toggle="yes">de novo</italic> pathogenic variant. Because simplex cases (i.e., a single occurrence in a family) have not yet been evaluated sufficiently to determine if the pathogenic variant occurred <italic toggle="yes">de novo</italic>, the proportion of FH caused by <italic toggle="yes">de novo</italic> pathogenic variants is unknown but appears to be very low.</p>
            </list-item>
            <list-item>
              <p>If the pathogenic variant found in the proband cannot be detected in leukocyte DNA of either parent, two possible explanations are germline mosaicism in a parent or a <italic toggle="yes">de novo</italic> pathogenic variant in the proband. Although no instances of germline mosaicism have been reported, it remains a possibility.</p>
            </list-item>
            <list-item>
              <p>Recommendations for the evaluation of parents of a proband with an apparent <italic toggle="yes">de novo</italic> pathogenic variant include molecular genetic testing if the pathogenic variant has been identified in the proband, or cholesterol testing if the pathogenic variant has not been identified in the proband. Evaluation of parents may determine that one is affected but has escaped previous diagnosis because of a milder phenotypic presentation. Therefore, an apparently negative family history cannot be confirmed until appropriate evaluations have been performed.</p>
            </list-item>
            <list-item>
              <p>Note: Although most individuals diagnosed with FH have an affected parent, the family history may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or late onset of the disease in the affected parent.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to the sibs of the proband depends on the genetic status of the proband&#x02019;s parents.</p>
            </list-item>
            <list-item>
              <p>If a parent of the proband is affected or has a pathogenic variant, the risk to the sibs is 50%.</p>
            </list-item>
            <list-item>
              <p>If both parents of the proband are affected with FH or have a pathogenic variant, the risk to sibs of having FH is 50%, the risk to sibs having HoFH is 25%.</p>
            </list-item>
            <list-item>
              <p>When the parents are clinically unaffected, the risk to the sibs of a proband appears to be very low.</p>
            </list-item>
            <list-item>
              <p>The sibs of a proband with clinically unaffected parents are still at increased risk for familial hypercholesterolemia because of the possibility of reduced penetrance in a parent. However, this is a very unlikely scenario.</p>
            </list-item>
            <list-item>
              <p>If the pathogenic variant found in the proband cannot be detected in the leukocyte DNA of either parent, the risk to sibs is low but greater than that of the general population because of the theoretic possibility of parental germline mosaicism.</p>
            </list-item>
          </list>
          <p>
            <bold>Offspring of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Each child of an individual with FH has a 50% chance of inheriting the pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>If both parents of a child are affected with FH, the child has a 50% chance of having FH and a 25% chance of having HoFH.</p>
            </list-item>
          </list>
          <p><bold>Other family members.</bold> The risk to other family members depends on the status of the proband's parents. If a parent is affected or has a pathogenic variant, his or her family members may be at risk.</p>
          <p><bold>Considerations in families with an apparent <italic toggle="yes">de novo</italic> pathogenic variant.</bold> When neither parent of a proband with an autosomal dominant condition has the pathogenic variant identified in the proband, the pathogenic variant is likely <italic toggle="yes">de novo</italic>. However, possible non-medical explanations including alternate paternity or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored.</p>
        </sec>
        <sec id="hyperchol.Risk_to_Family_Members__Homozy">
          <title>Risk to Family Members &#x02014; Homozygous Familial Hypercholesterolemia (HoFH)</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected individual are obligate heterozygotes and thus have one familial hypercholesterolemia-related pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>Individuals with one pathogenic variant have FH.</p>
            </list-item>
          </list>
          <p><bold>Sibs of a proband.</bold> The risk to sibs of having FH is 50%; the risk to sibs of having HoFH is 25%.</p>
          <p><bold>Offspring of a proband.</bold> The offspring of an individual with HoFH are obligate heterozygotes for a pathogenic variant; thus, all will have FH.</p>
          <p><bold>Other family members.</bold> Sibs of the proband's parents are at 50% risk of having a pathogenic variant and, thus, FH.</p>
        </sec>
        <sec id="hyperchol.Related_Genetic_Counseling_Iss">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="hyperchol.Evaluation_of_Relatives_at_Ris">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p><bold>Specific risk issues.</bold> Individuals inheriting pathogenic variants from both parents will develop a severe form of familial hypercholesterolemia (HoFH).</p>
          <p><bold>Predictive genetic testing</bold> for asymptomatic adult family members at risk for FH requires prior identification of the pathogenic variant in the family.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="hyperchol.Prenatal_Testing_and_Preimplan">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the pathogenic variant has been identified in a family member with FH (or if both pathogenic variants have been identified in a family member with HoFH), prenatal testing for a pregnancy at increased risk or preimplantation genetic diagnosis are possible.</p>
          <p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
        </sec>
      </sec>
      <sec id="hyperchol.Resources">
        <title>Resources</title>
      </sec>
      <sec id="hyperchol.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p>
          <bold>
            <italic toggle="yes">APOB</italic>
          </bold>
        </p>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">APOB</italic> is 42,216 base pairs in length, comprising 28 introns and 29 exons. It has an open reading frame of 13,692 bases.</p>
        <p>The distribution of the introns within the gene is unusual in that 24 of the 29 introns occur in the 5' terminus. More than half of the protein is coded by the 7,572-bp exon 26, one of the largest exons reported in the human genome. One of the two main isoforms, apoB-100, synthesized exclusively in the liver, is responsible for complications related to FH [<xref ref-type="bibr" rid="hyperchol.REF.whitfield.2004.1725">Whitfield et al 2004</xref>]. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="hyperchol" object-id="hyperchol.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Pathogenic variants.</bold> More than five pathogenic variants have been reported to be associated with FH, two of which are repeatedly found to be significant:</p>
        <list list-type="bullet">
          <list-item>
            <p>p.Arg3527Gln, found mainly in people with European ancestry</p>
          </list-item>
          <list-item>
            <p>p.Arg3527Trp, which tends to be found mostly within Asian populations [<xref ref-type="bibr" rid="hyperchol.REF.calandra.2011.1885">Calandra et al 2011</xref>]</p>
          </list-item>
        </list>
        <p>Pathogenic variants in this locus account for approximately 1%-5% of all persons with FH.</p>
        <table-wrap id="hyperchol.T.apob_selected_pathogenic_var" orientation="portrait" position="anchor">
          <label>Table 5. </label>
          <caption>
            <p><italic toggle="yes">APOB</italic> Selected Pathogenic Variants</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_hyperchol.T.apob_selected_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                <th id="hd_h_hyperchol.T.apob_selected_pathogenic_var_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                <th id="hd_h_hyperchol.T.apob_selected_pathogenic_var_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_hyperchol.T.apob_selected_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.10580G&#x0003e;A&#x000a0;<sup>2</sup><break/>(9775G&#x0003e;A)</td>
                <td headers="hd_h_hyperchol.T.apob_selected_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg3527Gln<break/>(Arg3500Gln)</td>
                <td headers="hd_h_hyperchol.T.apob_selected_pathogenic_var_1_1_1_3" rowspan="3" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000384.2">NM_000384.2</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_000375.2">NP_000375.2</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_hyperchol.T.apob_selected_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.10579C&#x0003e;T<break/>(9774C&#x0003e;T)</td>
                <td headers="hd_h_hyperchol.T.apob_selected_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg3527Trp<break/>(Arg3500Trp)</td>
              </tr>
              <tr>
                <td headers="hd_h_hyperchol.T.apob_selected_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.10672C&#x0003e;T</td>
                <td headers="hd_h_hyperchol.T.apob_selected_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg3558Cys</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
            <fn>
              <p>Amino acids are numbered from the beginning of the protein precursor, including signal sequence, and nucleotides from first base of the ATG initiation codon.</p>
            </fn>
            <fn id="hyperchol.TF.5.1">
              <label>1. </label>
              <p>Variant designation that does not conform to current naming conventions. In this case, numbering is based on mature peptide before cleavage of signal peptide and corresponding nucleotides.</p>
            </fn>
            <fn id="hyperchol.TF.5.2">
              <label>2. </label>
              <p>
                <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://uswest.ensembl.org/Homo_sapiens/Variation/Summary?r=2:21228660-21229660;toggle_HGVS_names=open;v=rs5742904;vdb=variation;vf=3917324">rs5742904</ext-link>
              </p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold> The gene product is the main apolipoprotein of chylomicrons and low-density lipoproteins. Human <italic toggle="yes">APOB</italic> mRNA is 14.5 kb in length and codes for a mature protein of 4560 amino acids [<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://genome.ucsc.edu/cgi-bin/hgGene?hgg_gene=uc002red.3&#x00026;hgg_prot=NP_000375&#x00026;hgg_chrom=chr2&#x00026;hgg_start=21224300&#x00026;hgg_end=21266945&#x00026;hgg_type=knownGene&#x00026;db=hg19&#x00026;hgsid=341540851">UCSC Genome Browser, <italic toggle="yes">APOB</italic></ext-link>; accessed July 10, 2013].</p>
        <p><italic toggle="yes">APOB</italic> has four functional domains [<xref ref-type="bibr" rid="hyperchol.REF.innerarity.1990.1337">Innerarity et al 1990</xref>]:</p>
        <list list-type="bullet">
          <list-item>
            <p>Synthesis, assembly, and secretion of hepatic triglyceride-rich lipoproteins</p>
          </list-item>
          <list-item>
            <p>Binding of lipids and serving as a structural component of very low-density lipoproteins (VLDL) and LDL</p>
          </list-item>
          <list-item>
            <p>Binding of heparin and various proteoglycans found in the arterial wall</p>
          </list-item>
          <list-item>
            <p>Interaction with the LDL receptor, important for clearance of LDL from plasma</p>
          </list-item>
        </list>
        <p><bold>Abnormal gene product.</bold>
<italic toggle="yes">APOB</italic> is generally involved in aiding the binding of LDL-C to its receptor on the cell surface. <italic toggle="yes">APOB</italic> pathogenic variants alter the ability of protein to effectively bind LDL-C to <italic toggle="yes">LDLR</italic>, causing fewer LDL-C particles to be removed from the blood.</p>
        <p>
          <bold>
            <italic toggle="yes">LDLR</italic>
          </bold>
        </p>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">LDLR</italic> spans 45 kb, comprising 18 exons and 17 introns. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="hyperchol" object-id="hyperchol.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Pathogenic variants.</bold> Pathogenic variants have been reported in the promoter, introns, and exons of <italic toggle="yes">LDLR</italic>. The majority of pathogenic variants fall within the ligand-binding (40%) or epidermal growth factor precursor-like (47%) domains, with the highest frequency of pathogenic variants reported in exon 4 (20%) [<xref ref-type="bibr" rid="hyperchol.REF.leigh.2008.485">Leigh et al 2008</xref>, <xref ref-type="bibr" rid="hyperchol.REF.usifo.2012.387">Usifo et al 2012</xref>]. More than 1500 <italic toggle="yes">LDLR</italic> pathogenic variants have been reported in the University College London (UCL) database, highlighting the molecular heterogeneity of the disorder. A complete list of reported variants can be found in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ucl.ac.uk/ldlr/Current/">British Heart Foundation database</ext-link>. Some associations with specific ethnic groups are also mentioned. Variants have also been entered in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/clinvar/">ClinVar</ext-link> database.</p>
        <table-wrap id="hyperchol.T.ldlr_selected_pathogenic_var" orientation="portrait" position="anchor">
          <label>Table 6. </label>
          <caption>
            <p><italic toggle="yes">LDLR</italic> Selected Pathogenic Variants</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_hyperchol.T.ldlr_selected_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                <th id="hd_h_hyperchol.T.ldlr_selected_pathogenic_var_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                <th id="hd_h_hyperchol.T.ldlr_selected_pathogenic_var_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_hyperchol.T.ldlr_selected_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x0003e;15-kb del&#x000a0;<sup>1</sup><break/>(5&#x02019; of gene through exon 1)</td>
                <td headers="hd_h_hyperchol.T.ldlr_selected_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
                <td headers="hd_h_hyperchol.T.ldlr_selected_pathogenic_var_1_1_1_3" rowspan="2" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000527.4">NM_000527.4</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/protein/NP_000518.1">NP_000518.1</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_hyperchol.T.ldlr_selected_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">5-kb del&#x000a0;<sup>1</sup><break/>(deletion of exons 2 and 3)</td>
                <td headers="hd_h_hyperchol.T.ldlr_selected_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature. <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>).</p>
            </fn>
            <fn id="hyperchol.TF.6.1">
              <label>1. </label>
              <p>Variant designation that does not conform to current naming conventions</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold>
<italic toggle="yes">LDLR</italic> encodes a mature protein product of 839 amino acids [<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_000518.1">NP_000518.1</ext-link>]. LDLR has four distinct functional domains that can function independently of each other [<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi?seqinput=NP_001182729.1">NCBI Conserved LDLR Domains</ext-link>; accessed July 10, 2013]:</p>
        <list list-type="bullet">
          <list-item>
            <p>LDL receptor domain class A (LDLa)</p>
          </list-item>
          <list-item>
            <p>Epidermal growth factor-like domain (EGF)</p>
          </list-item>
          <list-item>
            <p>Calcium-binding EGF-like domain (EGF-CA)</p>
          </list-item>
          <list-item>
            <p>LDL receptor repeat class B (LDLb)</p>
          </list-item>
        </list>
        <p>LDLR consists of cell surface proteins involved in endocytosis of LDL cholesterol (LDL-C). After LDL-C is bound at the cell membrane, it is taken into the cell and to lysosomes where the protein moiety is degraded and the cholesterol molecule suppresses cholesterol synthesis via negative feedback.</p>
        <p><bold>Abnormal gene product.</bold> Pathogenic variants in <italic toggle="yes">LDLR</italic> usually either reduce the number of LDL receptors produced within the cells or disrupt the ability of the receptor to bind LDL-C. Either way, heterozygous pathogenic variants in <italic toggle="yes">LDLR</italic> cause high levels of plasma LDL-C [<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://genome.ucsc.edu/cgi-bin/hgGene?hgg_gene=uc002mqk.4&#x00026;hgg_prot=P01130&#x00026;hgg_chrom=chr19&#x00026;hgg_start=11200037&#x00026;hgg_end=11244505&#x00026;hgg_type=knownGene&#x00026;db=hg19&#x00026;hgsid=341540851">UCSC Genome Browser, LDLR</ext-link>; accessed July 10, 2013].</p>
        <p>
          <bold>
            <italic toggle="yes">PCSK9</italic>
          </bold>
        </p>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">PCSK9</italic> has a transcript size of 25,378 bp and 12 exons. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="hyperchol" object-id="hyperchol.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Pathogenic variants.</bold> Approximately 100 variants in <italic toggle="yes">PCSK9</italic> have been submitted to the University College London database [<xref ref-type="bibr" rid="hyperchol.REF.abifadel.2003.154">Abifadel et al 2003</xref>]. Although many are hypothesized to be pathogenic, few have been consistently and significantly associated with FH [<xref ref-type="bibr" rid="hyperchol.REF.naoumova.2005.2654">Naoumova et al 2005</xref>]. A complete list of reported variants can be found at the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ucl.ac.uk/ldlr/Current/index.php?select_db=PCSK9">University College London (British Heart Foundation) database</ext-link> and in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/clinvar/">ClinVar</ext-link>.</p>
        <table-wrap id="hyperchol.T.pcsk9_selected_pathogenic_va" orientation="portrait" position="anchor">
          <label>Table 7. </label>
          <caption>
            <p><italic toggle="yes">PCSK9</italic> Selected Pathogenic Variants</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_hyperchol.T.pcsk9_selected_pathogenic_va_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                <th id="hd_h_hyperchol.T.pcsk9_selected_pathogenic_va_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                <th id="hd_h_hyperchol.T.pcsk9_selected_pathogenic_va_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_hyperchol.T.pcsk9_selected_pathogenic_va_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.381T&#x0003e;A</td>
                <td headers="hd_h_hyperchol.T.pcsk9_selected_pathogenic_va_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ser127Arg</td>
                <td headers="hd_h_hyperchol.T.pcsk9_selected_pathogenic_va_1_1_1_3" rowspan="5" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_174936.3">NM_174936.3</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_777596.2">NP_777596.2</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_hyperchol.T.pcsk9_selected_pathogenic_va_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.644G&#x0003e;A</td>
                <td headers="hd_h_hyperchol.T.pcsk9_selected_pathogenic_va_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg215His</td>
              </tr>
              <tr>
                <td headers="hd_h_hyperchol.T.pcsk9_selected_pathogenic_va_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.646T&#x0003e;C</td>
                <td headers="hd_h_hyperchol.T.pcsk9_selected_pathogenic_va_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Phe216Leu</td>
              </tr>
              <tr>
                <td headers="hd_h_hyperchol.T.pcsk9_selected_pathogenic_va_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1120G&#x0003e;T</td>
                <td headers="hd_h_hyperchol.T.pcsk9_selected_pathogenic_va_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Asp374Tyr</td>
              </tr>
              <tr>
                <td headers="hd_h_hyperchol.T.pcsk9_selected_pathogenic_va_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1486C&#x0003e;T</td>
                <td headers="hd_h_hyperchol.T.pcsk9_selected_pathogenic_va_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg496Trp</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors.&#x000a0;<italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic>&#x000a0;follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold>
<italic toggle="yes">PCSK9</italic> encodes a protein consisting of 692 amino acids and three main domains:</p>
        <list list-type="bullet">
          <list-item>
            <p>Prodomain</p>
          </list-item>
          <list-item>
            <p>Catalytic domain</p>
          </list-item>
          <list-item>
            <p>C-terminal domain</p>
          </list-item>
        </list>
        <p><bold>Abnormal gene product.</bold> The <italic toggle="yes">PCSK9</italic> protein product binds to LDL lipid receptors and promotes their degradation in intracellular acidic compartments.</p>
        <p>Pathogenic variants in this gene have been associated both with hypercholesterolemia and hypocholesterolemia.</p>
        <list list-type="bullet">
          <list-item>
            <p>Gain-of-function pathogenic variants cause hypercholesterolemia by excessive degradation of LDLRs, reducing the amount of LDL-C removed from the blood.</p>
          </list-item>
          <list-item>
            <p>Loss-of-function pathogenic variants cause hypocholesterolemia (reduced blood cholesterol levels) by increasing the number of LDLRs on the surface of liver cells, resulting in a quicker than usual removal of LDL-C from the blood and reduced incidence of coronary artery disease [<xref ref-type="bibr" rid="hyperchol.REF.cohen.2006.1264">Cohen et al 2006</xref>, <xref ref-type="bibr" rid="hyperchol.REF.pandit.2008.1333">Pandit et al 2008</xref>].</p>
          </list-item>
        </list>
      </sec>
      <sec id="hyperchol.References">
        <title>References</title>
        <sec id="hyperchol.Published_GuidelinesConsensus">
          <title>Published Guidelines/Consensus Statements</title>
          <ref-list id="hyperchol.Published_GuidelinesConsensus.reflist0">
            <ref id="hyperchol.REF1">
              <mixed-citation publication-type="web">American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Failure Society of America; Heart Rhythm Society; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons, Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.sciencedirect.com/science/article/pii/S0022522311011287">online</ext-link>. 2011. Accessed 12-2-16.</mixed-citation>
            </ref>
            <ref id="hyperchol.REF.daniels.2008">
              <mixed-citation publication-type="web">Daniels SR, Greer FR; Committee on Nutrition. 2008. Lipid screening and cardiovascular health in childhood. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pediatrics.aappublications.org/content/122/1/198.long">online</ext-link>. 2008. Accessed 11-21-16.</mixed-citation>
            </ref>
            <ref id="hyperchol.REF.demott.2008">
              <mixed-citation publication-type="web">DeMott K, Nherera L, Shaw EJ, Minhas R, Humphries SE, Kathoria M, Ritchie G, Nunes V, Davies D, Lee P, McDowell I, Neil A, Qureshi N, Rowlands P, Seed M, Stracey H, Thorogood M, Watson M. Clinical guidelines and evidence review for familial hypercholesterol&#x000e6;mia: the identification and management of adults and children with familial hypercholesterol&#x000e6;mia. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/books/NBK53822/">online</ext-link>. 2008. Accessed 11-21-16.</mixed-citation>
            </ref>
            <ref id="hyperchol.REF.descamps.2011">
              <mixed-citation publication-type="web">Descamps OS, Tenoutasse S, Stephenne X, Gies I, Beauloye V, Lebrethon MC, De Beaufort C, De Waele K, Scheen A, Rietzschel E, Mangano A, Panier JP, Ducobu J, Langlois M, Balligand JL, Legat P, Blaton V, Muls E, Van Gaal L, Sokal E, Rooman R, Carpentier Y, De Backer G, Heller FR. Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, p&#x000e6;diatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.sciencedirect.com/science/article/pii/S0021915011004977">online</ext-link>. 2011. Accessed 11-21-16.</mixed-citation>
            </ref>
            <ref id="hyperchol.REF.goldberg.2011">
              <mixed-citation publication-type="web">Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, Daniels SR, Gidding SS, de Ferranti SD, Ito MK, McGowan MP, Moriarty PM, Cromwell WC, Ross JL, Ziajka PE; National Lipid Association Expert Panel on Familial Hypercholesterolemia. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.sciencedirect.com/science/article/pii/S1933287411005629">online</ext-link>. 2011. Accessed 11-21-16.</mixed-citation>
            </ref>
            <ref id="hyperchol.REF.hopkins.2011">
              <mixed-citation publication-type="web">Hopkins PN, Toth PP, Ballantyne CM, Rader DJ; National Lipid Association Expert Panel on Familial Hypercholesterolemia. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.sciencedirect.com/science/article/pii/S1933287411005320">online</ext-link>. 2011. Accessed 11-21-16.</mixed-citation>
            </ref>
            <ref id="hyperchol.REF.ito.2011">
              <mixed-citation publication-type="web">Ito MK, McGowan MP, Moriarty PM; National Lipid Association Expert Panel on Familial Hypercholesterolemia. 2011. Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.sciencedirect.com/science/article/pii/S1933287411005368">online</ext-link>. 2011. Accessed 11-21-16.</mixed-citation>
            </ref>
            <ref id="hyperchol.REF.martin.2013">
              <mixed-citation publication-type="web">Martin AC, Coakley J, Forbes DA, Sullivan DR, Watts GF. Familial hypercholesterol&#x000e6;mia in children and adolescents: a new p&#x000e6;diatric model of care. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://onlinelibrary.wiley.com/doi/10.1111/jpc.12036/abstract;jsessionid=83E385513B5486853C97B04C2408ECAF.f03t04">online</ext-link>. 2013. Accessed 11-21-16.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="hyperchol.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="hyperchol.Literature_Cited.reflist0">
            <ref id="hyperchol.REF.abifadel.2003.154">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Abifadel</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Varret</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rab&#x000e8;s</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allard</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ouguerram</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Devillers</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cruaud</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benjannet</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wickham</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Erlich</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Derr&#x000e9;</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vill&#x000e9;ger</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Farnier</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beucler</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruckert</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chambaz</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chanu</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lecerf</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Luc</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moulin</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weissenbach</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prat</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krempf</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Junien</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seidah</surname>
                    <given-names>NG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boileau</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.</article-title>
                <source>Nat Genet.</source>
                <year>2003</year>
                <volume>34</volume>
                <fpage>154</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">12730697</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.andersen.2016.443">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Andersen</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ibarra</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andersen</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <article-title>Current familial hypercholesterolemia diagnostic criteria underdiagnose APOB mutations: Lessons from the Amish community.</article-title>
                <source>J Clin Lipidol.</source>
                <year>2016</year>
                <volume>10</volume>
                <fpage>443</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">27055977</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.austin.2004.407">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Austin</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hutter</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zimmern</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Humphries</surname>
                    <given-names>SE</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review.</article-title>
                <source>Am J Epidemiol.</source>
                <volume>160</volume>
                <fpage>407</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">15321837</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.awan.2013.218">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Awan</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Choi</surname>
                    <given-names>HY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stitziel</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruel</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bamimore</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Husa</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gagnon</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peloso</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hegele</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seidah</surname>
                    <given-names>NG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kathiresan</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Genest</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>APOE p.Leu167del mutation in familial hypercholesterolemia.</article-title>
                <source>Atherosclerosis.</source>
                <year>2013</year>
                <volume>231</volume>
                <fpage>218</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">24267230</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.benn.2012.3956">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Benn</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watts</surname>
                    <given-names>GF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tybjaerg-Hansen</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nordestgaard</surname>
                    <given-names>BG</given-names>
                  </name>
                </person-group>
                <article-title>Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2012</year>
                <volume>97</volume>
                <fpage>3956</fpage>
                <lpage>64</lpage>
                <pub-id pub-id-type="pmid">22893714</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.bertolini.2013.342">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bertolini</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pisciotta</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rabacchi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cefal&#x000f9;</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Noto</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fasano</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Signori</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fresa</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Averna</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Calandra</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy.</article-title>
                <source>Atherosclerosis.</source>
                <year>2013</year>
                <volume>227</volume>
                <fpage>342</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">23375686</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.brahm.2016.131">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brahm</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hegele</surname>
                    <given-names>RA</given-names>
                  </name>
                </person-group>
                <article-title>Combined hyperlipidemia: familial but not (usually) monogenic.</article-title>
                <source>Curr Opin Lipidol.</source>
                <year>2016</year>
                <volume>27</volume>
                <fpage>131</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">26709473</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.burnett.2012.20">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Burnett</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bell</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hooper</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hegele</surname>
                    <given-names>RA</given-names>
                  </name>
                </person-group>
                <article-title>Clinical utility gene card for: Familial Hypobetalipoproteinaemia (APOB).</article-title>
                <source>Eur J Hum Genet.</source>
                <year>2012</year>
                <fpage>20</fpage>
                <pub-id pub-id-type="pmid">21811303</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.calandra.2011.1885">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Calandra</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tarugi</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Speedy</surname>
                    <given-names>HE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dean</surname>
                    <given-names>AF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertolini</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shoulders</surname>
                    <given-names>CC</given-names>
                  </name>
                </person-group>
                <article-title>Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk.</article-title>
                <source>J Lipid Res.</source>
                <year>2011</year>
                <volume>52</volume>
                <fpage>1885</fpage>
                <lpage>926</lpage>
                <pub-id pub-id-type="pmid">21862702</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.cariou.2011.258">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cariou</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Le May</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Costet</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Clinical aspects of PCSK9.</article-title>
                <source>Atherosclerosis.</source>
                <volume>216</volume>
                <fpage>258</fpage>
                <lpage>65</lpage>
                <pub-id pub-id-type="pmid">21596380</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.civeira.2004.55">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Civeira</surname>
                    <given-names>F.</given-names>
                  </name>
                </person-group>
                <article-title>Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia.</article-title>
                <source>Atherosclerosis.</source>
                <year>2004</year>
                <volume>173</volume>
                <fpage>55</fpage>
                <lpage>68</lpage>
                <pub-id pub-id-type="pmid">15177124</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.cohen.2006.1264">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boerwinkle</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mosley</surname>
                    <given-names>TH</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Hobbs</surname>
                    <given-names>HH</given-names>
                  </name>
                </person-group>
                <article-title>Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.</article-title>
                <source>N Engl J Med.</source>
                <year>2006</year>
                <volume>354</volume>
                <fpage>1264</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">16554528</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.cuchel.2014.2146">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cuchel</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruckert</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ginsberg</surname>
                    <given-names>HN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raal</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santos</surname>
                    <given-names>RD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hegele</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuivenhoven</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nordestgaard</surname>
                    <given-names>BG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Descamps</surname>
                    <given-names>OS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steinhagen-Thiessen</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tybj&#x000e6;rg-Hansen</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watts</surname>
                    <given-names>GF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Averna</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boileau</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bor&#x000e9;n</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Catapano</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Defesche</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hovingh</surname>
                    <given-names>GK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Humphries</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kovanen</surname>
                    <given-names>PT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Masana</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pajukanta</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parhofer</surname>
                    <given-names>KG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ray</surname>
                    <given-names>KK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stalenhoef</surname>
                    <given-names>AF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stroes</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taskinen</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wiegman</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wiklund</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chapman</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <collab>European Atherosclerosis Society Consensus Panel on Familial Hypercholesterolaemia</collab>
                </person-group>
                <article-title>Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society.</article-title>
                <source>Eur Heart J.</source>
                <year>2014</year>
                <volume>35</volume>
                <fpage>2146</fpage>
                <lpage>57</lpage>
                <pub-id pub-id-type="pmid">25053660</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.de_castroor_s.2010.53">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>De Castro-Or&#x000f3;s</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pocov&#x000ed;</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Civeira</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <article-title>The genetic basis of familial hypercholesterolemia: inheritance, linkage, and mutations.</article-title>
                <source>Appl Clin Genet.</source>
                <year>2010</year>
                <volume>3</volume>
                <fpage>53</fpage>
                <lpage>64</lpage>
                <pub-id pub-id-type="pmid">23776352</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.dedoussis.2004.443">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dedoussis</surname>
                    <given-names>GV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmidt</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Genschel</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>LDL-receptor mutations in Europe.</article-title>
                <source>Hum Mutat.</source>
                <year>2004</year>
                <volume>24</volume>
                <fpage>443</fpage>
                <lpage>59</lpage>
                <pub-id pub-id-type="pmid">15523646</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.degoma.2016.240">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>deGoma</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ahmad</surname>
                    <given-names>ZS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Brien</surname>
                    <given-names>EC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kindt</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shrader</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Newman</surname>
                    <given-names>CB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pokharel</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baum</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hemphill</surname>
                    <given-names>LC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hudgins</surname>
                    <given-names>LC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ahmed</surname>
                    <given-names>CD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gidding</surname>
                    <given-names>SS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duffy</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neal</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilemon</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roe</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rader</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ballantyne</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Linton</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duell</surname>
                    <given-names>PB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shapiro</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moriarty</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knowles</surname>
                    <given-names>JW</given-names>
                  </name>
                </person-group>
                <article-title>Treatment gaps in adults with heterozygous familial hypercholesterolemia in the United States: Data From the CASCADE-FH Registry.</article-title>
                <source>Circ Cardiovasc Genet.</source>
                <year>2016</year>
                <volume>9</volume>
                <fpage>240</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">27013694</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.dey.2013">
              <mixed-citation publication-type="other">Dey A, Aggarwal R, Dwivedi S. Cardiovascular profile of xanthelasma palpebrarum. Biomed Res Int. 2013;2013:932863</mixed-citation>
            </ref>
            <ref id="hyperchol.REF.elis.2011.223">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Elis</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhou</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stein</surname>
                    <given-names>EA</given-names>
                  </name>
                </person-group>
                <article-title>Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades.</article-title>
                <source>Am J Cardiol.</source>
                <year>2011</year>
                <volume>108</volume>
                <fpage>223</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">21545982</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.fahed.2011.23">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fahed</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nemer</surname>
                    <given-names>GM</given-names>
                  </name>
                </person-group>
                <article-title>Familial hypercholesterolemia: the lipids or the genes?</article-title>
                <source>Nutr Metab (Lond)</source>
                <year>2011</year>
                <volume>8</volume>
                <fpage>23</fpage>
                <pub-id pub-id-type="pmid">21513517</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF28">
              <mixed-citation publication-type="web">FDA. Withdrawal of approval of indications related to the coadministration with statins in applications for niacin extended-release tablets and fenofibric acid delayed-release capsules. Federal Register. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.federalregister.gov/documents/2016/04/18/2016-08887/abbvie-inc-et-al-withdrawal-of-approval-of-indications-related-to-the-coadministration-with-statins">online</ext-link>. 2016. Accessed 11-21-16.</mixed-citation>
            </ref>
            <ref id="hyperchol.REF.fung.2011">
              <mixed-citation publication-type="other">Fung M, Hill J, Cook D, Frohlich J. Case series of type III hyperlipoproteinemia in children. BMJ Case Rep. 2011 Jun 9;2011. doi: <pub-id pub-id-type="doi">10.1136/bcr.02.2011.3895</pub-id>.</mixed-citation>
            </ref>
            <ref id="hyperchol.REF.gidding.2015.2167">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gidding</surname>
                    <given-names>SS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Champagne</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Ferranti</surname>
                    <given-names>SD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Defesche</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ito</surname>
                    <given-names>MK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knowles</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCrindle</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raal</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rader</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santos</surname>
                    <given-names>RD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lopes-Virella</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watts</surname>
                    <given-names>GF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wierzbicki</surname>
                    <given-names>AS</given-names>
                  </name>
                  <collab>American Heart Association Atherosclerosis, Hypertension, and Obesity in Young Committee of Council on Cardiovascular Disease in Young, Council on Cardiovascular and Stroke Nursing, Council on Functional Genomics and Translational Biology, and Council on Lifestyle and Cardiometabolic Health</collab>
                </person-group>
                <article-title>The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association.</article-title>
                <source>Circulation.</source>
                <year>2015</year>
                <volume>132</volume>
                <fpage>2167</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">26510694</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.guyton.2013.1580">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Guyton</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Slee</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anderson</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fleg</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldberg</surname>
                    <given-names>RB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kashyap</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marcovina</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nash</surname>
                    <given-names>SD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Brien</surname>
                    <given-names>KD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weintraub</surname>
                    <given-names>WS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xu</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhao</surname>
                    <given-names>XQ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boden</surname>
                    <given-names>WE</given-names>
                  </name>
                </person-group>
                <article-title>Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes).</article-title>
                <source>J Am Coll Cardiol.</source>
                <year>2013</year>
                <volume>62</volume>
                <fpage>1580</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">23916935</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.haradashiba.2012.1043">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Harada-Shiba</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arai</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oikawa</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohta</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Okada</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Okamura</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nohara</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bujo</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yokote</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wakatsuki</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ishibashi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamashita</surname>
                    <given-names>S.</given-names>
                  </name>
                </person-group>
                <article-title>Guidelines for the management of familial hypercholesterolemia.</article-title>
                <source>J Atheroscler Thromb.</source>
                <year>2012</year>
                <volume>19</volume>
                <fpage>1043</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">23095242</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.hegele.2009.4189">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hegele</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ban</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hsueh</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kennedy</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cao</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zou</surname>
                    <given-names>GY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anand</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yusuf</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huff</surname>
                    <given-names>MW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>A polygenic basis for four classical Fredrickson hyperlipoproteinemia phenotypes that are characterized by hypertriglyceridemia.</article-title>
                <source>Hum Mol Genet.</source>
                <year>2009</year>
                <volume>18</volume>
                <fpage>4189</fpage>
                <lpage>94</lpage>
                <pub-id pub-id-type="pmid">19656773</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.hopkins.2011.s9">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hopkins</surname>
                    <given-names>PN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toth</surname>
                    <given-names>PP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ballantyne</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rader</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <collab>National Lipid Association Expert Panel on Familial Hypercholesterolemia</collab>
                </person-group>
                <article-title>Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.</article-title>
                <source>J Clin Lipidol.</source>
                <year>2011</year>
                <volume>5</volume>
                <fpage>S9</fpage>
                <lpage>17</lpage>
                <pub-id pub-id-type="pmid">21600530</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.horsthemke.1987.144">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Horsthemke</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dunning</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Humphries</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Identification of deletions in the human low density lipoprotein receptor gene.</article-title>
                <source>J Med Genet.</source>
                <year>1987</year>
                <volume>24</volume>
                <fpage>144</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">3572996</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.huang.1989.11394">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Huang</surname>
                    <given-names>LS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ripps</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korman</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deckelbaum</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Breslow</surname>
                    <given-names>JL</given-names>
                  </name>
                </person-group>
                <article-title>Hypobetalipoproteinemia due to an apolipoprotein B gene exon 21 deletion derived by Alu-Alu recombination.</article-title>
                <source>J Biol Chem.</source>
                <year>1989</year>
                <volume>264</volume>
                <fpage>11394</fpage>
                <lpage>400</lpage>
                <pub-id pub-id-type="pmid">2567736</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.huijgen.2012.354">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Huijgen</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hutten</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kindt</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vissers</surname>
                    <given-names>MN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kastelein</surname>
                    <given-names>JJ</given-names>
                  </name>
                </person-group>
                <article-title>Discriminative ability of LDL-cholesterol to identify patients with familial hypercholesterolemia: a cross-sectional study in 26,406 individuals tested for genetic FH.</article-title>
                <source>Circ Cardiovasc Genet.</source>
                <year>2012</year>
                <volume>5</volume>
                <fpage>354</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">22553281</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.huxley.2003.22">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Huxley</surname>
                    <given-names>RR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hawkins</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Humphries</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karpe</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neil</surname>
                    <given-names>HA</given-names>
                  </name>
                  <collab>Simon Broome Familial Hyperlipidaemia Register Group and Scientific Steering Committee</collab>
                </person-group>
                <article-title>Risk of fatal stroke in patients with treated familial hypercholesterolemia: a prospective registry study.</article-title>
                <source>Stroke.</source>
                <year>2003</year>
                <volume>34</volume>
                <fpage>22</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">12511745</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.innerarity.1990.1337">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Innerarity</surname>
                    <given-names>TL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mahley</surname>
                    <given-names>RW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weisgraber</surname>
                    <given-names>KH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bersot</surname>
                    <given-names>TP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krauss</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vega</surname>
                    <given-names>GL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grundy</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Friedl</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davignon</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCarthy</surname>
                    <given-names>BJ</given-names>
                  </name>
                </person-group>
                <article-title>Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia.</article-title>
                <source>J Lipid Res.</source>
                <year>1990</year>
                <volume>31</volume>
                <fpage>1337</fpage>
                <lpage>49</lpage>
                <pub-id pub-id-type="pmid">2280177</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.kassner.2014">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kassner</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>W&#x000fc;hle-Demuth</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Missala</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Humphries</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steinhagen-Thiessen</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Demuth</surname>
                    <given-names>I</given-names>
                  </name>
                </person-group>
                <article-title>Clinical utility gene card for: hyperlipoproteinemia, type II.</article-title>
                <source>Eur J Hum Genet.</source>
                <year>2014</year>
                <volume>22</volume>
                <issue>7</issue>
                <pub-id pub-id-type="pmid">24253857</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.kastelein.2008.1431">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kastelein</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Akdim</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stroes</surname>
                    <given-names>ES</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zwinderman</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bots</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stalenhoef</surname>
                    <given-names>AF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Visseren</surname>
                    <given-names>FL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sijbrands</surname>
                    <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trip</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stein</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gaudet</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duivenvoorden</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Veltri</surname>
                    <given-names>EP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marais</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Groot</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <article-title>ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia.</article-title>
                <source>N Engl J Med.</source>
                <year>2008</year>
                <volume>358</volume>
                <fpage>1431</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">18376000</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.khera.2016.2578">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Khera</surname>
                    <given-names>AV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Won</surname>
                    <given-names>HH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peloso</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lawson</surname>
                    <given-names>KS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bartz</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deng</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Leeuwen</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Natarajan</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Emdin</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bick</surname>
                    <given-names>AG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morrison</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brody</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gupta</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nomura</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kessler</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duga</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bis</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Duijn</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cupples</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Psaty</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rader</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Danesh</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schunkert</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McPherson</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Farrall</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watkins</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lander</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Correa</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boerwinkle</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Merlini</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ardissino</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saleheen</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gabriel</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kathiresan</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia.</article-title>
                <source>J Am Coll Cardiol.</source>
                <year>2016</year>
                <volume>67</volume>
                <fpage>2578</fpage>
                <lpage>89</lpage>
                <pub-id pub-id-type="pmid">27050191</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.langsted.2016.577">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Langsted</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kamstrup</surname>
                    <given-names>PR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benn</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tybj&#x000e6;rg-Hansen</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nordestgaard</surname>
                    <given-names>BG</given-names>
                  </name>
                </person-group>
                <article-title>High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study.</article-title>
                <source>Lancet Diabetes Endocrinol.</source>
                <year>2016</year>
                <volume>4</volume>
                <fpage>577</fpage>
                <lpage>87</lpage>
                <pub-id pub-id-type="pmid">27185354</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.leigh.2008.485">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Leigh</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Foster</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Whittall</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hubbart</surname>
                    <given-names>CS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Humphries</surname>
                    <given-names>SE</given-names>
                  </name>
                </person-group>
                <article-title>Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database.</article-title>
                <source>Ann Hum Genet.</source>
                <year>2008</year>
                <volume>72</volume>
                <fpage>485</fpage>
                <lpage>98</lpage>
                <pub-id pub-id-type="pmid">18325082</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.martinez.2016.504">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Martinez</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brodlie</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Griesemer</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kato</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harren</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gordon</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parker</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levine</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tyberg</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Starc</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cho</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Min</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elmore</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lobritto</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hudgins</surname>
                    <given-names>LC</given-names>
                  </name>
                </person-group>
                <article-title>Effects of liver transplantation on lipids and cardiovascular disease in children with homozygous familial hypercholesterolemia.</article-title>
                <source>Am J Cardiol.</source>
                <year>2016</year>
                <volume>118</volume>
                <fpage>504</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">27365335</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.motazacker.2012.1360">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Motazacker</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pirruccello</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huijgen</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Do</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gabriel</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peter</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuivenhoven</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Defesche</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kastelein</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hovingh</surname>
                    <given-names>GK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zelcer</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kathiresan</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fouchier</surname>
                    <given-names>SW</given-names>
                  </name>
                </person-group>
                <article-title>Advances in genetics show the need for extending screening strategies for autosomal dominant hypercholesterolaemia.</article-title>
                <source>Eur Heart J.</source>
                <year>2012</year>
                <volume>33</volume>
                <fpage>1360</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">22408029</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.naoumova.2005.2654">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Naoumova</surname>
                    <given-names>RP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tosi</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patel</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neuwirth</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horswell</surname>
                    <given-names>SD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marais</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Heyningen</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soutar</surname>
                    <given-names>AK</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response.</article-title>
                <source>Arterioscler Thromb Vasc Biol</source>
                <volume>25</volume>
                <fpage>2654</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">16224054</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.naukkarinen.2006.285">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Naukkarinen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ehnholm</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peltonen</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <article-title>Genetics of familial combined hyperlipidemia.</article-title>
                <source>Curr Opin Lipidol.</source>
                <year>2006</year>
                <volume>17</volume>
                <fpage>285</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">16680034</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.ned.2011.rrn1238">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ned</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sijbrands</surname>
                    <given-names>EJ</given-names>
                  </name>
                </person-group>
                <article-title>Cascade screening for familial hypercholesterolemia (FH).</article-title>
                <source>PLoS Curr.</source>
                <year>2011</year>
                <volume>3</volume>
                <fpage>RRN1238</fpage>
                <pub-id pub-id-type="pmid">21633520</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.nordestgaard.2013.3478">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nordestgaard</surname>
                    <given-names>BG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chapman</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Humphries</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ginsberg</surname>
                    <given-names>HN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Masana</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Descamps</surname>
                    <given-names>OS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wiklund</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hegele</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raal</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Defesche</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wiegman</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santos</surname>
                    <given-names>RD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watts</surname>
                    <given-names>GF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parhofer</surname>
                    <given-names>KG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hovingh</surname>
                    <given-names>GK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kovanen</surname>
                    <given-names>PT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boileau</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Averna</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bor&#x000e9;n</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruckert</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Catapano</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuivenhoven</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pajukanta</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ray</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stalenhoef</surname>
                    <given-names>AF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stroes</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taskinen</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tybj&#x000e6;rg-Hansen</surname>
                    <given-names>A</given-names>
                  </name>
                  <collab>European Atherosclerosis Society Consensus Panel</collab>
                </person-group>
                <article-title>Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society.</article-title>
                <source>Eur Heart J.</source>
                <year>2013</year>
                <volume>34</volume>
                <fpage>3478</fpage>
                <lpage>90a</lpage>
                <pub-id pub-id-type="pmid">23956253</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.pandit.2008.1333">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pandit</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wisniewski</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santoro</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ha</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramakrishnan</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cubbon</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cummings</surname>
                    <given-names>RT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wright</surname>
                    <given-names>SD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sparrow</surname>
                    <given-names>CP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sitlani</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fisher</surname>
                    <given-names>TS</given-names>
                  </name>
                </person-group>
                <article-title>Functional analysis of sites within PCSK9 responsible for hypercholesterolemia.</article-title>
                <source>J Lipid Res.</source>
                <year>2008</year>
                <volume>49</volume>
                <fpage>1333</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">18354137</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.perez_de_isla.2016.1278">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Perez de Isla</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alonso</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watts</surname>
                    <given-names>GF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mata</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saltijeral Cerezo</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mu&#x000f1;iz</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fuentes</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Diaz-Diaz</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Andr&#x000e9;s</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zamb&#x000f3;n</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rubio-Marin</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barba-Romero</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saenz</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanchez Mu&#x000f1;oz-Torrero</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martinez-Faedo</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miramontes-Gonzalez</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Badim&#x000f3;n</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mata</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>SAFEHEART Investigators. Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART Registry follow-up.</article-title>
                <source>J Am Coll Cardiol.</source>
                <year>2016</year>
                <volume>67</volume>
                <fpage>1278</fpage>
                <lpage>85</lpage>
                <pub-id pub-id-type="pmid">26988947</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.raal.2013.7">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Raal</surname>
                    <given-names>FJ</given-names>
                  </name>
                </person-group>
                <article-title>Lomitapide for homozygous familial hypercholesterolaemia.</article-title>
                <source>Lancet.</source>
                <year>2013</year>
                <volume>381</volume>
                <fpage>7</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">23122767</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.raal.2015.341">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Raal</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Honarpour</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blom</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hovingh</surname>
                    <given-names>GK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xu</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scott</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wasserman</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stein</surname>
                    <given-names>EA</given-names>
                  </name>
                </person-group>
                <article-title>TESLA Investigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.</article-title>
                <source>Lancet.</source>
                <year>2015</year>
                <volume>385</volume>
                <fpage>341</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">25282520</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.raal.2012.262">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Raal</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santos</surname>
                    <given-names>RD</given-names>
                  </name>
                </person-group>
                <article-title>Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment.</article-title>
                <source>Atherosclerosis.</source>
                <year>2012</year>
                <volume>223</volume>
                <fpage>262</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">22398274</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.raal.2010.998">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Raal</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santos</surname>
                    <given-names>RD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blom</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marais</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Charng</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cromwell</surname>
                    <given-names>WC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lachmann</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gaudet</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tan</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chasan-Taber</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tribble</surname>
                    <given-names>DL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Flaim</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crooke</surname>
                    <given-names>ST</given-names>
                  </name>
                </person-group>
                <article-title>Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.</article-title>
                <source>Lancet.</source>
                <year>2010</year>
                <volume>375</volume>
                <fpage>998</fpage>
                <lpage>1006</lpage>
                <pub-id pub-id-type="pmid">20227758</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.raal.2016a.238">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Raal</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sjouke</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hovingh</surname>
                    <given-names>GK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Isaac</surname>
                    <given-names>BF</given-names>
                  </name>
                </person-group>
                <article-title>Phenotype diversity among patients with homozygous familial hypercholesterolemia: A cohort study.</article-title>
                <source>Atherosclerosis.</source>
                <year>2016a</year>
                <volume>248</volume>
                <fpage>238</fpage>
                <lpage>44</lpage>
                <pub-id pub-id-type="pmid">27017151</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.raal.2016b.1458">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Raal</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sjouke</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hovingh</surname>
                    <given-names>GK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Isaac</surname>
                    <given-names>BF</given-names>
                  </name>
                </person-group>
                <article-title>Retrospective analysis of cohort database: Phenotypic variability in a large dataset of patients confirmed to have homozygous familial hypercholesterolemia.</article-title>
                <source>Data Brief.</source>
                <year>2016b</year>
                <volume>7</volume>
                <fpage>1458</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">27182539</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.rader.2003.1795">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rader</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hobbs</surname>
                    <given-names>HH</given-names>
                  </name>
                </person-group>
                <article-title>Monogenic hypercholesterolemia: new insights in pathogenesis and treatment.</article-title>
                <source>J Clin Invest.</source>
                <year>2003</year>
                <volume>111</volume>
                <fpage>1795</fpage>
                <lpage>803</lpage>
                <pub-id pub-id-type="pmid">12813012</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.reiner.2011.1769">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Reiner</surname>
                    <given-names>&#x0017d;</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Catapano</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Backer</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Graham</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taskinen</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wiklund</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Agewall</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alegria</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chapman</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Durrington</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Erdine</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Halcox</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hobbs</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kjekshus</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filardi</surname>
                    <given-names>PP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Riccardi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Storey</surname>
                    <given-names>RF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wood</surname>
                    <given-names>D</given-names>
                  </name>
                  <collab>Clinical Practice Guidelines Committee of the Spanish Society of Cardiology</collab>
                </person-group>
                <article-title>ESC/EAS Guidelines for the management of dyslipidaemias.</article-title>
                <source>Eur Heart J.</source>
                <year>2011</year>
                <volume>32</volume>
                <fpage>1769</fpage>
                <lpage>818</lpage>
                <pub-id pub-id-type="pmid">21712404</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.scientific_steering_committee.1991.893">
              <element-citation publication-type="journal">
                <person-group>
                  <collab>Scientific Steering Committee</collab>
                </person-group>
                <article-title>Scientific Steering Committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia.</article-title>
                <source>BMJ</source>
                <year>1991</year>
                <volume>303</volume>
                <fpage>893</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">1933004</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.simard.2004.202">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Simard</surname>
                    <given-names>LR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Viel</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lambert</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paradis</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levy</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delvin</surname>
                    <given-names>EE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mitchell</surname>
                    <given-names>GA</given-names>
                  </name>
                </person-group>
                <article-title>The Delta&#x0003e;15 Kb deletion French Canadian founder mutation in familial hypercholesterolemia: rapid polymerase chain reaction-based diagnostic assay and prevalence in Quebec.</article-title>
                <source>Clin Genet.</source>
                <year>2004</year>
                <volume>65</volume>
                <fpage>202</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">14756670</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.slack.1969.1380">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Slack</surname>
                    <given-names>J.</given-names>
                  </name>
                </person-group>
                <article-title>Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states.</article-title>
                <source>Lancet.</source>
                <year>1969</year>
                <volume>2</volume>
                <fpage>1380</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">4188273</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.starr.2008.791">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Starr</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hadfield</surname>
                    <given-names>SG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hutten</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lansberg</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leren</surname>
                    <given-names>TP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Damgaard</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neil</surname>
                    <given-names>HA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Humphries</surname>
                    <given-names>SE</given-names>
                  </name>
                </person-group>
                <article-title>Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing.</article-title>
                <source>Clin Chem Lab Med.</source>
                <year>2008</year>
                <volume>46</volume>
                <fpage>791</fpage>
                <lpage>803</lpage>
                <pub-id pub-id-type="pmid">18601600</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.stone.1974.476">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stone</surname>
                    <given-names>NJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levy</surname>
                    <given-names>RI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fredrickson</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verter</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia.</article-title>
                <source>Circulation.</source>
                <year>1974</year>
                <volume>49</volume>
                <fpage>476</fpage>
                <lpage>88</lpage>
                <pub-id pub-id-type="pmid">4813182</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.stone.2014.2889">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stone</surname>
                    <given-names>NJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robinson</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lichtenstein</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bairey Merz</surname>
                    <given-names>CN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blum</surname>
                    <given-names>CB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eckel</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldberg</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gordon</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levy</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lloyd-Jones</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McBride</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwartz</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shero</surname>
                    <given-names>ST</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>SC</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Watson</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>PW</given-names>
                  </name>
                  <collab>American College of Cardiology/American Heart Association Task Force on Practice Guidelines</collab>
                </person-group>
                <article-title>2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.</article-title>
                <source>J Am Coll Cardiol.</source>
                <year>2014</year>
                <volume>63</volume>
                <fpage>2889</fpage>
                <lpage>934</lpage>
                <pub-id pub-id-type="pmid">24239923</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.talmud.2013.1293">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Talmud</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shah</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Whittall</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Futema</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Howard</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cooper</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harrison</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Drenos</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karpe</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neil</surname>
                    <given-names>HA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Descamps</surname>
                    <given-names>OS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Langenberg</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lench</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kivimaki</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Whittaker</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hingorani</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kumari</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Humphries</surname>
                    <given-names>SE</given-names>
                  </name>
                </person-group>
                <article-title>Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study.</article-title>
                <source>Lancet.</source>
                <year>2013</year>
                <volume>381</volume>
                <fpage>1293</fpage>
                <lpage>301</lpage>
                <pub-id pub-id-type="pmid">23433573</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.tsouli.2005.236">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tsouli</surname>
                    <given-names>SG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kiortsis</surname>
                    <given-names>DN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Argyropoulou</surname>
                    <given-names>MI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mikhailidis</surname>
                    <given-names>DP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elisaf</surname>
                    <given-names>MS</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Pathogenesis, detection and treatment of Achilles tendon xanthomas.</article-title>
                <source>Eur J Clin Invest.</source>
                <volume>35</volume>
                <fpage>236</fpage>
                <lpage>44</lpage>
                <pub-id pub-id-type="pmid">15816992</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.usifo.2012.387">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Usifo</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leigh</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Whittall</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lench</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yeats</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orengo</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Celli</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Humphries</surname>
                    <given-names>SE</given-names>
                  </name>
                </person-group>
                <article-title>Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment.</article-title>
                <source>Ann Hum Genet</source>
                <year>2012</year>
                <volume>76</volume>
                <fpage>387</fpage>
                <lpage>401</lpage>
                <pub-id pub-id-type="pmid">22881376</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.versmissen.2008.a2423">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Versmissen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oosterveer</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yazdanpanah</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Defesche</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Basart</surname>
                    <given-names>DC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liem</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heeringa</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Witteman</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lansberg</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kastelein</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sijbrands</surname>
                    <given-names>EJ</given-names>
                  </name>
                </person-group>
                <article-title>Efficacy of statins in familial hypercholesterolaemia: a long term cohort study.</article-title>
                <source>BMJ</source>
                <year>2008</year>
                <volume>337</volume>
                <fpage>a2423</fpage>
                <pub-id pub-id-type="pmid">19001495</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.vuorio.2013.315">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vuorio</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Docherty</surname>
                    <given-names>KF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Humphries</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuoppala</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kovanen</surname>
                    <given-names>PT</given-names>
                  </name>
                </person-group>
                <article-title>Statin treatment of children with familial hypercholesterolemia--trying to balance incomplete evidence of long-term safety and clinical accountability: are we approaching a consensus?</article-title>
                <source>Atherosclerosis.</source>
                <year>2013</year>
                <volume>226</volume>
                <fpage>315</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">23141908</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.wald.2016.1628">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wald</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bestwick</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morris</surname>
                    <given-names>JK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Whyte</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jenkins</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wald</surname>
                    <given-names>NJ</given-names>
                  </name>
                </person-group>
                <article-title>Child-parent familial hypercholesterolemia screening in primary care.</article-title>
                <source>N Engl J Med.</source>
                <year>2016</year>
                <volume>375</volume>
                <fpage>1628</fpage>
                <lpage>37</lpage>
                <pub-id pub-id-type="pmid">27783906</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.whitfield.2004.1725">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Whitfield</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barrett</surname>
                    <given-names>PH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Bockxmeer</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burnett</surname>
                    <given-names>JR</given-names>
                  </name>
                </person-group>
                <article-title>Lipid disorders and mutations in the APOB gene.</article-title>
                <source>Clin Chem.</source>
                <year>2004</year>
                <volume>50</volume>
                <fpage>1725</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">15308601</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.wierzbicki.2008.a1095">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wierzbicki</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Humphries</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minhas</surname>
                    <given-names>R</given-names>
                  </name>
                  <collab>Guideline Development Group</collab>
                </person-group>
                <article-title>Familial hypercholesterolaemia: summary of NICE guidance.</article-title>
                <source>BMJ</source>
                <year>2008</year>
                <volume>337</volume>
                <fpage>a1095</fpage>
                <pub-id pub-id-type="pmid">18753174</pub-id>
              </element-citation>
            </ref>
            <ref id="hyperchol.REF.williams.1993.319s">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Williams</surname>
                    <given-names>RR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hunt</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hopkins</surname>
                    <given-names>PN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wu</surname>
                    <given-names>LL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hasstedt</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berry</surname>
                    <given-names>TD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barlow</surname>
                    <given-names>GK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stults</surname>
                    <given-names>BM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schumacher</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ludwig</surname>
                    <given-names>EH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elbein</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>DE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lifton</surname>
                    <given-names>RP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lalouel</surname>
                    <given-names>JM</given-names>
                  </name>
                </person-group>
                <article-title>Genetic basis of familial dyslipidemia and hypertension: 15-year results from Utah.</article-title>
                <source>Am J Hypertens.</source>
                <year>1993</year>
                <volume>6</volume>
                <fpage>319S</fpage>
                <lpage>327S</lpage>
                <pub-id pub-id-type="pmid">8297539</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="hyperchol.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="hyperchol.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>8 December 2016 (sw) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>2 January 2014 (me) Review posted live</p>
            </list-item>
            <list-item>
              <p>5 August 2013 (jl) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec sec-type="figs-and-tables">
        <title/>
        <fig position="float" id="hyperchol.F1" orientation="portrait">
          <label>Figure 1. </label>
          <caption>
            <p>LDL cholesterol burden in individuals with or without familial hypercholesterolemia as a function of the age of initiation of statin therapyData derived from <xref ref-type="bibr" rid="hyperchol.REF.starr.2008.791">Starr et al [2008]</xref> and <xref ref-type="bibr" rid="hyperchol.REF.huijgen.2012.354">Huijgen et al [2012]</xref>. Figure from <xref ref-type="bibr" rid="hyperchol.REF.nordestgaard.2013.3478">Nordestgaard et al [2013]</xref>; used by permission of Oxford University Press.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="hyperchol-Image001" position="anchor" orientation="portrait"/>
        </fig>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
